Introduction {#s1}
============

Thanks to their ability to inhibit cell wall biosynthesis, β-lactams remained the first-line defense against bacterial infections for over 20 years, before resistant bacteria appeared in clinical practice.

Resistance to this class of drugs can be the result of antibiotic target site alteration, prevention of antibiotic access by altered permeability or forced efflux, or antibiotic degradation (Wilke et al., [@B212]). The latter, represents the primary resistance mechanism in Gram-negative bacteria producing β-lactamase enzymes able to covalently bind the carbonyl moiety of the β-lactam ring and hydrolyze its amide bond (Fisher et al., [@B71]). Naturally occurring chromosomally located β-lactamases are quite common in Gram-negative bacteria; likely evolved from penicillin-binding proteins, when produced in small quantity they do not significantly contribute to antibiotic resistance. It was the appearance of the first plasmid-mediated β-lactamase TEM-1 (Datta and Kontomichalou, [@B51]) to designate the beginning of an unstoppable phenomenon in the 1960s. Ever since, the introduction of new natural or synthetic drugs to replace old ones in an attempt to limit the insurgence of antibiotic resistant bacteria triggered a chain reaction providing bacteria with a constant selective pressure driving the expansion of different resistance mechanisms (Medeiros, [@B133]).

In recent years β-lactamases have extensively diversified in response to the clinical use of new generations of β-lactams (penicillin, cephalosporins, carbapenems, and monobactams) leading to the need of classification schemes. Based on primary structure (Ambler, [@B9]), enzymatic properties and biochemical attributes (Bush et al., [@B33]), and the increasingly available amino acid sequences (Bush and Jacoby, [@B32]) four major classes (A, B, C, D) can be acknowledged. Serine β-lactamases belonging to class A are the most abundant (Philippon et al., [@B160]), with more than 500 enzymes, including the most clinically significant extended spectrum β-lactamases (ESBL) variants, i.e., CTX-M-, TEM-, and SHV-type enzymes (Bush and Fisher, [@B31]).

Although, SHV enzymes did not undergo the explosive dissemination observed for CTX-M-type variants (Canton et al., [@B38]), in recent years they have been found in several Enterobacteriaceae outside of the typical clinical hosts *Klebsiella pneumoniae* and *Escherichia coli*, with a rising allele variability (<http://www.lahey.org/studies>), and in different environmental niches. Many admirable works describing the biochemistry, the genetics and the evolution of SHV β-lactamases have appeared over the last years. The aim of this review is to provide the readers with an updated overview on SHV β-lactamases, their amino acid variants and spectrum of activity, and to describe the occurrence of plasmid-associated SHV enzymes in Enterobacteriaceae and their epidemiological significance.

Origin and diversity of the SHV family {#s2}
======================================

The first *bla*~SHV-1~ gene was identified in the 1970s in *E. coli* (Pitton, [@B163]). The encoded enzyme SHV−1 (sulfhydryl reagent variable) proved its activity against penicillins and first generation cephalosporins (Matthew et al., [@B131]) and was confirmed part of the conjugative plasmid p453 (Barthélémy et al., [@B17]; Table [1](#T1){ref-type="table"}). The most likely ancestor of the plasmid-mediated SHV−1 is a chromosomal species-specific penicillinase detected in fecal *K. pneumoniae* isolates from neonates (Haeggman et al., [@B77]). The enzyme showed a typical antibiogram with penicillin rather than cephalosporin resistance and a marked inhibition by clavulanic acid. How *bla*~SHV-1~ moved from the chromosome to the plasmid does not have a conclusive explanation since the proposed association with a transposable element (Nugent and Hedges, [@B151]) has not been confirmed.

###### 

**SHV-type extended-spectrum β-lactamases**.

  **Gene[^§^](#TN1){ref-type="table-fn"}**           **Accession Number**       **pI**    **Isolation**   **Bacterial Species**   **Genetic background**                    **References**                                                                                                                 
  -------------------------------------------------- -------------------------- --------- --------------- ----------------------- ----------------------------------------- ------------------------------- ----- -------- ------------------------------------------------------------------------------- -----------------------------------------------
  *bla*~SHV-1~[^\*\*^](#TN3){ref-type="table-fn"}    [AF148850](AF148850)       7.6       NA              1972                    *E. coli*                                 p^453^                          Yes   ND       ND                                                                              Pitton, [@B163]; Matthew et al., [@B131]
  *bla*~SHV-2~                                       [AF148851](AF148851)       7.6       Germany         1983                    *K. ozaenae*                              p^BP60^                         Yes   45       ND                                                                              Kliebe et al., [@B108]
  *bla*~SHV-2a~                                      [X98102](X98102)           7.6       Germany         1987--1988              *K. pneumoniae*                           p^ZMP1^                         Yes   66       ND                                                                              Podbielski et al., [@B164]
  *bla*~SHV-3~                                       [KX092356](KX092356)       7.0       France          1986                    *K. pneumoniae*                           p^UD18^                         Yes   180      ND                                                                              Nicolas et al., [@B147]
  *bla*~SHV-4~                                       NA                         7.8       France          1987                    *K. pneumoniae*                           P                               Yes   180      ND                                                                              Péduzzi et al., [@B158]; Arlet et al., [@B14]
  *bla*~SHV-5~                                       [X55640](X55640)           8.2       Chile           1987                    *K. pneumoniae*                           p^AFF1^                         No    150      ND                                                                              Gutmann et al., [@B75]
  *bla*~SHV-6~                                       [Y11069.1](Y11069.1)       7.6       France          1991                    *K. pneumoniae*                           p^SLH06^                        Yes   180      ND                                                                              Arlet et al., [@B12]
  *bla*~SHV-7~                                       [U20270](U20270)           7.6       USA             1993                    *E. coli*                                 P                               Yes   10       ND                                                                              Bradford et al., [@B29]
  *bla*~SHV-8~                                       [U92041](U92041)           7.6       USA             1990                    *E. coli*                                 C                               --    --       --                                                                              Rasheed et al., [@B175]
  *bla*~SHV-9~                                       [S82452.1](S82452.1)       8.2       Greece          1995                    *E. coli; K. pneumoniae; S. marcescens*   p^K318-1^; p^E77-1^; p^S24-1^   Yes   ND       ND                                                                              Prinarakis et al., [@B170]
  *bla*~SHV-11~[^\*\*^](#TN3){ref-type="table-fn"}   [X98101](X98101)           8.2       Switzerland     1993--1995              *K. pneumoniae*                           P                               Yes   80       ND                                                                              Nüesch-Inderbinen et al., [@B150]
  *bla*~SHV-12~                                      [JX268741](JX268741)       8.2       Switzerland     1993--1995              *E. coli; K. pneumoniae*                  P                               Yes   80       ND                                                                              Nüesch-Inderbinen et al., [@B150]
  *bla*~SHV-13~                                      [AF164577](AF164577)       7.6       Netherlands     1994                    *K. pneumoniae*                           P                               Yes   170      ND                                                                              Yuan et al., [@B217]
  *bla*~SHV-15~                                      [AJ011428.2](AJ011428.2)   ND        India           1998                    *E. coli*                                 ND                              ND    ND       ND                                                                              <http://www.lahey.org/studies/>
  *bla*~SHV-16~                                      [AF072684.2](AF072684.2)   7.6       France          1996                    *K. pneumoniae*                           P                               Yes   \>100    --                                                                              Arpin et al., [@B16]
  *bla*~SHV-18~                                      [AF132290](AF132290)       7.8       USA             1994                    *K. pneumoniae*                           P                               Yes   80       ND                                                                              Rasheed et al., [@B174]
  *bla*~SHV-23~                                      [AF117747](AF117747)       ND        South Africa    1990                    *K. pneumoniae*                           ND                              ND    ND       ND                                                                              Essack et al., [@B66]
  *bla*~SHV-24~                                      [AB023477](AB023477)       7.5       Japan           1996                    *E. coli*                                 p^CAZR001^                      Yes   150      ND                                                                              Kurokawa et al., [@B110]
  *bla*~SHV-27~                                      [AF293345.1](AF293345.1)   8.2       Brazil          1999                    *K. pneumoniae*                           C                               --    --       ND                                                                              Corkill et al., [@B49]
  *bla*~SHV-30~                                      [AY661885](AY661885)       6.7       USA             2003                    *E. cloacae*                              P                               ND    9.4      AmpC, *bla*~TEM-1~ and *bla*~SHV-7~                                             Szabó et al., [@B193]
  *bla*~SHV-31~                                      [AY277255](AY277255)       7.8       Netherlands     2001                    *K. pneumoniae*                           C                               --    --       --                                                                              Mazzariol et al., [@B132]
  *bla*~SHV-34~                                      [AY036620](AY036620)       ND        USA             1998--2000              *C. koseri; E. coli; K. pneumoniae*       p^OZ185^                        Yes   \>100    ND                                                                              Heritage et al., [@B86]
  *bla*~SHV-38~                                      [AY079099](AY079099)       7.6       France          2001                    *K. pneumoniae*                           C                               --    --       --                                                                              Poirel et al., [@B165]
  *bla*~SHV-40~                                      [AF535128](AF535128)       7.6       Canada          1999--2000              *K. pneumoniae*                           ND                              ND    ND       ND                                                                              Mulvey et al., [@B138]
  *bla*~SHV-41~                                      [AF535129](AF535129)       7.6       Canada          1999--2000              *K. pneumoniae*                           ND                              ND    ND       ND                                                                              Mulvey et al., [@B138]
  *bla*~SHV-42~                                      [AF535130](AF535130)       7.6       Canada          1999--2000              *K. pneumoniae*                           ND                              ND    ND       ND                                                                              Mulvey et al., [@B138]
  *bla*~SHV-45~                                      [AF547625](AF547625)       8.2       Brazil          NA                      *K. pneumoniae*                           IncA/C                          ND    97-145   *bla*~CTX-M-2~ and *bla*~SHV-27~                                                Dropa et al., [@B59]
  *bla*~SHV-46~                                      [AY210887](AY210887)       8.2       New York        1998                    *K. oxytoca*                              P                               Yes   70       *bla*~TEM-1~; *bla*~OXY-2~; *bla*~KPC-2~; *bla*~OXA\ (?)~                       Yigit et al., [@B216]
  *bla*~SHV-55~                                      [DQ054528](DQ054528)       ND        Portugal        NA                      *K. pneumoniae*                           ND                              No    --       TEM1                                                                            Mendonça et al., [@B134]
  *bla*~SHV-57~                                      [AY223863](AY223863)       8.3       Taiwan          1998                    *E. coli*                                 p^MTY512^                       Yes   40--60   ND                                                                              Ma et al., [@B120]
  *bla*~SHV-64~                                      [DQ174304](DQ174304)       ND        China           2000--2002              *K. pneumoniae*                           ND                              ND    ND       ND                                                                              Zuo et al., [@B221]
  *bla*~SHV-66~                                      [DQ174306](DQ174306)       ND        China           2000--2002              *K. pneumoniae*                           ND                              ND    ND       ND                                                                              Zuo et al., [@B221]
  *bla*~SHV-70~                                      [DQ013287](DQ013287)       7.6       China           2003--2004              *E. cloacae*                              p^EC04^                         Yes   ND       ND                                                                              Ling et al., [@B116]
  *bla*~SHV-86~                                      [DQ328802](DQ328802)       8.2       Colombia        2003                    *K. pneumoniae*                           P                               Yes   ND       ND                                                                              Espinal et al., [@B65]
  *bla*~SHV-90~                                      NA                         8.2       Portugal        2003                    *K. pneumoniae*                           ND                              ND    ND       ND                                                                              Machado et al., [@B121]
  *bla*~SHV-91~                                      NA                         7.6       Portugal        2003                    *K. pneumoniae*                           ND                              ND    ND       ND                                                                              Machado et al., [@B121]
  *bla*~SHV-98~                                      [AM941844](AM941844)       7.6       Algeria         2005                    *K. pneumoniae*                           ND                              ND    ND       ND                                                                              Ramdani-Bouguessa et al., [@B171]
  *bla*~SHV-99~                                      [AM941845](AM941845)       7.8       Algeria         2005                    *K. pneumoniae*                           ND                              ND    ND       ND                                                                              Ramdani-Bouguessa et al., [@B171]
  *bla*~SHV-100~                                     [AM941846](AM941846)       7.2       Algeria         2005                    *K. pneumoniae*                           ND                              ND    ND       ND                                                                              Ramdani-Bouguessa et al., [@B171]
  *bla*~SHV-102~                                     [EU024485](EU024485)       ND        Spain           2003--2004              *E. coli*                                 ND                              ND    ND       ND                                                                              Vinué et al., [@B206]
  *bla*~SHV-104~                                     [EU274581](EU274581)       7,3/8,6   Tunisia         2004                    *K. pneumoniae*                           p^ML2011^                       Yes   50       ND                                                                              Ben Achour et al., [@B20]
  *bla*~SHV-105~                                     [FJ194944](FJ194944)       ND        USA             NA                      *K. pneumoniae*                           ND                              ND    ND       *bla*~SHV-1~; *bla*~SHV-5~                                                      Jones et al., [@B99]
  *bla*~SHV-106~                                     [AM941847](AM941847)       7.6       Portugal        1999                    *K. pneumoniae*                           ND                              ND    ND       *bla*~TEM-1~; *bla*~CTX-M-32~                                                   Mendonça et al., [@B135]
  *bla*~SHV-128~                                     [GU932590](GU932590)       8.6       Tunisia         2009                    *E. cloacae*                              IncFII (IS*26*)                 Yes   100      ND                                                                              Bourouis et al., [@B27]
  *bla*~SHV-129~                                     [GU827715](GU827715)       ND        Italy           2008                    *E. coli*                                 p^Ec6-66^                       ND    ND       ND                                                                              Lascols et al., [@B112]
  *bla*~SHV-134~                                     [HM559945](HM559945)       ND        Spain           2009                    *K. pneumoniae*                           IncFIIA (IS*26*)                Yes   75       *bla*~VIM-1~; *aac*(6′)-*Ib; dhfrII; aadA1; catB2; bla*~TEM-1~; *aac(3′)-Iia*   Sánchez-Romero et al., [@B182]
  *bla*~SHV-183~                                     [HG934764](HG934764)       ND        NA              NA                      *E. cloacae*                              ND                              ND    ND       ND                                                                              <http://www.lahey.org/studies/>

*Gene bla~SHV−115~ was not included in the table because no information is available (<http://www.lahey.org/studies>)*.

*Isolation or first description*.

*Non ESBL genes bla~SHV-1~ and bla~SHV-11~ are provided as reference*.

*P, plasmid; C, Chromosome; when known plasmid name or Inc/rep group, and Insertion Sequences are indicated*.

*NA, not available; ND, not determined*.

As of today, 189[^1^](#fn0001){ref-type="fn"} SHV allelic variants have been described, having developed resistance to 3rd generation cephalosporin (Tzouvelekis and Bonomo, [@B201]), monobactam and carbapenems (Poirel et al., [@B165]). Only a small proportion is biochemically and/or genetically characterized (<http://www.lahey.org/studies>). SHV β-lactamases can be divided into three subgroups on the basis of molecular characteristics or functional properties: (i) subgroup 2b (*n* = 37), able to hydrolyze penicillins and early cephalosporins (cephaloridine and cephalothin) and strongly inhibited by clavulanic acid and tazobactam; (ii) subgroup 2br (*n* = 7), broad-spectrum β-lactamases that acquired resistance to clavulanic acid; and (iii) subgroup 2be (*n* = 46), comprises ESBLs that can also hydrolyze one or more oxyimino β-lactams (cefotaxime, ceftazidime, and aztreonam). More than half of these variants (*n* = 99) has not been classified yet due to absence of biochemical characterization.

Figure [1](#F1){ref-type="fig"} illustrates a phylogenetic analysis of 149 out of the 189 SHV β-lactamase variants whose amino acid sequences were available online (<http://www.lahey.org/studies>), as of July 2016. Unlike other β-lactamase families (D\'andrea et al., [@B50]; Evans and Amyes, [@B67]), there is no clear clustering of the different subgroups, as also mirrored by gene based analysis (Supplementary Figure [S1](#SM2){ref-type="supplementary-material"}). Among the majority of unclassified variants, subgroup 2b and the few 2br variants are scattered all over the tree. Subgroup 2be showed clustering of most of the ESBL variants (including SHV-2a, SHV-5, and SHV-12), together with few non-classified enzymes (SHV−29, SHV−152, SHV−153, SHV−160, and SHV−165). It has been proposed that SHV β-lactamases descended from an unidentified ancestor holding an extended spectrum phenotype (2be) and that subgroup 2b derived from it (Hall and Barlow, [@B78]). Our analysis showed that several of SHV ESBL variants were scattered along the tree with short branch lengths with neighboring 2b or unknown variants within the SHV phylogeny (i.e., SHV−40, SHV−11, and SHV−35; Figure [1](#F1){ref-type="fig"}), supporting the hypothesis that they evolved from multiple variants, probably within the antibiotic era. Among the non-ESBL variants, *bla*~SHV-11~ represents one of the most successful and, together with *bla*~SHV-1~, the likely source of evolution for the existing SHV ESBL variants. *bla*~SHV-11~ was first identified as plasmid-encoded in clinical *K. pneumoniae* from Switzerland (Nüesch-Inderbinen et al., [@B150]) and ever since has been isolated worldwide.

![**Maximum likelihood amino acid tree of 149 SHV-type β-lactamases**. Variants whose sequence has not been released in GenBank as of July 2016, that show partial sequence or are identical to others (<http://www.lahey.org/studies/>) were not included in the analysis. SHV-180 and SHV-181 share the same sequence as well as SHV-121 and SHV-136. The tree was implemented in Mega version 6.06 (Tamura et al., [@B194]). Solid circles represent: red, extended-spectrum β-lactamases (2be; *n* = 46); green, broad-spectrum β-lactamases (2br, *n* = 5); and blue, penicillinases (2b, *n* = 30). Unclassified alleles are reported in black (*n* = 68).](fmicb-07-01374-g0001){#F1}

Although, nearly displaced, together with TEM, by CTX-M enzymes over the years (Canton et al., [@B38]), 46 ESBL *bla*~SHV~ genes have been described so far (Table [1](#T1){ref-type="table"}). The first report of SHV-mediated resistance to third-generation cephalosporins was in 1983 with the isolation and characterization of *bla*~SHV-2~, encoded by plasmid pBP60 in a German clinical isolate of *Klebsiella ozaenae* and showing only a few nucleotide mismatches with *bla*~SHV-1~ (Kliebe et al., [@B108]). In a few years four other ESBL variants were identified as plasmid-encoded in clinical *K. pneumoniae*, showing variable gene homologies with the *bla*~SHV-1~ and *bla*~SHV-2~ sequences (50--90%): *bla*~SHV-2*a*~ encoded by conjugative plasmid pZMP1 (Podbielski et al., [@B164]); *bla*~SHV-3~ on pUD18 (Nicolas et al., [@B147]); *bla*~SHV-4~, widely disseminated from France as a result of a single *K. pneumoniae* clone diffusion (Arlet et al., [@B14], [@B13]); and *bla*~SHV-5~ able to hydrolyze broad-spectrum cephalosporins and monobactams (Gutmann et al., [@B75]). Of these first variants, the most epidemiologically successful were *bla*~SHV-2*a*~ and *bla*~SHV-5~, which will be further discussed, together with *bla*~SHV-2~ and *bla*~SHV-12~, in a dedicated paragraph (Section Expansion toward New Ecological Niches). Interestingly, *bla*~SHV-3~ and *bla*~SHV-4~ have been only sporadically detected since their first description. *bla*~SHV-3~ seems to be geographically restricted to the USA where it was detected in *E. coli* of animal origin, associated with other antibiotic resistance genes such as *bla*~CTX-*M*-15~, *bla*~CTX-*M*-24~, *bla*~CMY-2~, and/or *bla*~TEM-1~ (Shaheen et al., [@B184]). *bla*~SHV-4~ was identified also in *Enterobacter aerogenes* and *Citrobacter diversus* in different countries (Arpin et al., [@B15]; El Harrif-Heraud et al., [@B64]; Pitout et al., [@B162]).

The last two decades witnessed the appearance of several new variants (*bla*~SHV-7~, *bla*~SHV-8~, *bla*~SHV-9~, *bla*~SHV-31~, *bla*~SHV-38~, *bla*~SHV-40~, *bla*~SHV-41~, and *bla*~SHV-42~) whose dissemination was restricted to limited cases (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). A few variants seem to be geographically constrained: (i) *bla*~SHV-106~, only described in Portuguese isolates of *K. pneumoniae* together with *bla*~TEM-1~, and/or *bla*~CTX-*M*-32~ (Mendonça et al., [@B135]); (ii) *bla*~SHV-55~, in Portugal (Mendonça et al., [@B134]; Machado et al., [@B121]) and recently in Brazil (Dropa et al., [@B59]); and (iii) *bla*~SHV-57~, in *E. coli* isolates from Taiwan and China (Ma et al., [@B120]; Tian et al., [@B197]). A variant worth to mention is *bla*~SHV-27~ (Corkill et al., [@B49]), that has been detected on different plasmids in *E. coli, K. pneumoniae* and *Enterobacter cloacae*, associated with a vast array of antibiotic resistance genes (*bla*~DHA−1~, *bla*~TEM-1~, *bla*~TEM−1b~, *bla*~CMY-2~, *bla*~IMP~, *bla*~CTX-*M*-14~, *bla*~CTX-*M*-15~, *bla*~SHV-12~, *bla*~SHV-45~, *bla*~OXA-1~, *dfrA5, ereA2*; Muratani et al., [@B140]; Abbassi et al., [@B1]; Kiratisin et al., [@B107]; Duval et al., [@B61]; Hammami et al., [@B80]).

Most of SHV ESBLs (25 out of 46) are unique cases, with only one report so far. Seventeen variants are exclusively found in clinical *K. pneumoniae*: *bla*~SHV-6~, *bla*~SHV-13~, *bla*~SHV-16~, *bla*~SHV-18~, *bla*~SHV-23~, *bla*~SHV-45~, *bla*~SHV-64~,*bla*~SHV-66~, *bla*~SHV-86~, *bla*~SHV-90~, *bla*~SHV-91~, *bla*~SHV-98~, *bla*~SHV-99~, *bla*~SHV-100~,*bla*~SHV−104~,*bla*~SHV-105~, and *bla*~SHV-134~. These variants have been described worldwide (Brazil, Portugal, Algeria, USA, Tunisia, Netherlands, France, South Africa, Colombia, and China) and are mostly associated to plasmids (Table [1](#T1){ref-type="table"}). Some of these variants are sporadically accompanied by other antibiotic resistance genes like in the case of: (i) *bla*~SHV-45~ encoded by an IncA/C plasmid together with *bla*~CTX-*M*-2~ and *bla*~SHV-27~ (Dropa et al., [@B59]); (ii) *bla*~SHV-134~ encoded by an IncFII plasmid accompanied by a second plasmid carrying *bla*~VIM−1~ (Sánchez-Romero et al., [@B182]); (iii) and *bla*~SHV-105~, conferring reduced susceptibility to ceftazidime, ceftriaxone, and aztreonam together with *bla*~SHV-1~, and *bla*~SHV-5~ (Jones et al., [@B99]). One of the oldest variants, *bla*~SHV-6~, was only described in France in 1991 in a *K. pneumoniae* clinical case (Arlet et al., [@B12]). It might be speculated that the 180 kb plasmid encoding *bla*~SHV-6~ and conferring decreased susceptibility to ceftazidime and aztreonam was not stable or it reduced bacterial strain fitness preventing a successful dissemination.

Four variants have been described only in clinical *E. coli*: (i) *bla*~SHV-15~, described together with *bla*~CMY-2~ in a strain imported from India into the United Kingdom (<http://www.lahey.org/studies/>); (ii) *bla*~SHV-24~, identified in Japan on a transferable 150 Kb plasmid conferring high-level resistance to ceftazidime but not cefotaxime and cefazolin (Kurokawa et al., [@B110]); emergence of SHV-24 might have been driven by the extensive use of ceftazidime in Japan, enabling bacterial survival in high concentrations of this drug; (iii) *bla*~SHV-102~, recovered in a Spanish hospital and hydrolyzing cefotaxime and ceftazidime (Vinué et al., [@B206]); (iv) and *bla*~SHV-129~, detected in an abscess specimen from a patient hospitalized in Italy in 2008 (Lascols et al., [@B112]).

*bla*~SHV-46~ was only described on a 70 Kb conjugative plasmid also carrying *bla*~TEM-1~ and *bla*~KPC−2~ in a carbapenem-resistant strain of *Klebsiella oxytoca* from the urine of a hospitalized patient in New York (USA) in 1998 (Yigit et al., [@B216]). Finally, *bla*~SHV-34~ is an interesting example of extended-spectrum β-lactamase encoded by an epidemic plasmid circulating among *Citrobacter koseri, E. coli*, and *K. pneumoniae* in the same US hospital between 1998 and 2000 (Heritage et al., [@B86]).

Majority of SHV ESBLs have been detected in *K. pneumoniae* or *E. coli* (Table [1](#T1){ref-type="table"}). *bla*~SHV-30~ was the first variant to be detected in an *E. cloacae* isolate from a blood culture from a solid-organ transplant recipient in the USA in 2003 (Szabó et al., [@B193]). The gene, previously described in *K. pneumoniae* and *Salmonella* (Mulvey et al., [@B138]; Whichard et al., [@B211]), was located on a 9.4 Kb plasmid and contributed together with chromosomal *ampC, bla*~SHV-7~, and *bla*~TEM-1~ to the antibiotic resistance profile of the *E. cloacae* isolate, the first of its kind producing two different SHV enzymes. Three other novel ESBL variants have been solely identified as plasmid-encoded in clinical *E. cloacae*: (i) *bla*~SHV-70~, from a Chinese patient with history of ceftazidime treatment (Ling et al., [@B116]) and observed in other clinical Chinese settings (Liu et al., [@B118]); (ii) *bla*~SHV-128~, isolated in Tunisia in 2009, located on an IncFII conjugative plasmid, and conferring resistance to all β-lactams except imipenem (Bourouis et al., [@B27]); (iii) and *bla*~SHV-183~, for which additional description is not available (<http://www.lahey.org/studies/>).

SHV extended-spectrum β-lactamases: catalytic properties and resistance phenotype {#s3}
=================================================================================

Extended-spectrum SHV β-lactamases belong to functional group 2be, while very recently they were assigned to subclass A1 of serine β-lactamases, clustering with TEM and CTX-M enzymes among other clinically relevant β-lactamases (Bush, [@B30]; Philippon et al., [@B160]). SHV ESBLs consist of two subdomains: an α/β that includes an antiparallel five-stranded β-sheet flanked by α-helices, and an all-α-helical subdomain (Matagne et al., [@B130]). Similar to TEM β-lactamases (Jelsch et al., [@B96]), the active site is located within the cleft created by the subdomains and it contains the Ser^70^ residue that mediates the nucleophilic attack on the carbonyl group of the β-lactam ring. In the vicinity of this serine residue, several conserved structural and functional amino acid motifs have been identified. These include the Ser^70^XXLys ("SXXK" motif, with X representing variable amino acids), the Ser^130^AspAsn ("SDN" motif), the Glu^166^XXLysAsn ("EXXLN" motif), and the Lys^234^Thr/SerGly ("KTG" motif) (Bush, [@B30]).

Each SHV ESBL has one (SHV-2, SHV-6, SHV-8, SHV-24, SHV-27, SHV-38, SHV-41, SHV-57, SHV-98, SHV-99, SHV-102, and SHV-104) to six (SHV-128) amino acid substitutions when compared to SHV-1 (Table [2](#T2){ref-type="table"}), indicating that even a single amino acid substitution is enough to convey an extended-spectrum phenotype. Therefore, we can speculate that other SHV ESBLs may still evolve from a parental SHV β-lactamase due to single spectrum-extending substitutions, although the majority of them have possibly emerged through a stepwise acquisition of several mutations (substitutions, deletions and/or insertions) from pre-existing extended-spectrum SHV variants.

###### 

**Amino acid polymorphisms in SHV-type extended-spectrum β-lactamases**.

                                              **Amino acid position**                                                                                                                                                                                               
  ------------------------------------------- ------------------------- --- --- --- --- --- --- ----- --- ----- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ----- --- --- ----- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
  SHV-1                                       Y                         I   L   S   T   P   A   L     R   G     R   E   V   V   E   H   Y   D   L   C   M   A   V   A   L   Q   G   D     L   D   M     A   A   K   L   T   R   R   G   E   A   S   E   R   N   I   L
  SHV-2                                       .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   S   .   .   .   .   .   .   .   .
  SHV-2A                                      .                         .   .   .   .   .   .   Q     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   S   .   .   .   .   .   .   .   .
  SHV-3                                       .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   L   S   .   .   .   .   .   .   .   .
  SHV-4                                       .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   L   S   K   .   .   .   .   .   .   .
  SHV-5                                       .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   S   K   .   .   .   .   .   .   .
  SHV-6                                       .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   A   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .
  SHV-7                                       .                         F   .   .   .   .   .   .     S   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   S   K   .   .   .   .   .   .   .
  SHV-8                                       .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   N   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .
  SHV-9                                       .                         .   .   .   .   .   .   .     .   Del   .   .   .   .   .   .   .   .   .   .   .   R   .   .   .   .   .   .     .   .   .     .   .   N   V   .   .   .   S   K   .   .   .   .   .   .   .
  SHV-11[^\*\*^](#TN6){ref-type="table-fn"}   .                         .   .   .   .   .   .   Q     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .
  SHV-12                                      .                         .   .   .   .   .   .   Q     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   S   K   .   .   .   .   .   .   .
  SHV-13                                      .                         .   .   .   .   .   .   Q     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   A   .   .   .   .   .   .   .   .
  SHV-15                                      .                         .   .   .   .   .   .   Q     .   .     .   .   .   M   K   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   S   K   .   .   .   .   .   .   .
  SHV-16                                      .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   T   H   .   .   .   .   .   .   .   .   .   .   Ins   .   .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .
  SHV-18                                      .                         F   .   .   .   .   .   .     S   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   A   K   .   .   .   .   .   .   .
  SHV-23[^\*^](#TN5){ref-type="table-fn"}     .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   F   .   .   .   .   .   .   .   .   .     .   .   .     .   G   .   .   .   .   .   S   K   .   .   .   .   .   .   .
  SHV-24                                      .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   G   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .
  SHV-27                                      .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   D   .     .   .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .
  SHV-30                                      .                         F   .   .   .   .   .   .     S   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   S   .   .   .   .   .   .   .   .
  SHV-31                                      .                         .   .   .   .   .   .   Q     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   .   K   .   .   .   .   .   .   .
  SHV-34                                      .                         F   .   .   .   .   .   .     S   .     .   G   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   S   .   .   .   .   .   .   .   .
  SHV-38                                      .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   V   .   .   .   .     .   .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .
  SHV-40                                      .                         .   .   .   .   .   .   Q     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   .   .   G   .   .   .   .   .   .
  SHV-41                                      .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   F   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .
  SHV-42                                      .                         .   .   .   .   .   S   .     .   .     .   .   .   .   .   .   .   .   .   .   V   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .
  SHV-45                                      .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   D   .     .   .   .     .   .   .   .   .   .   .   S   K   .   .   .   .   .   .   .
  SHV-46                                      .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   N   .   .   S   K   .   .   .   .   .   .   .
  SHV-55                                      F                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   S   K   .   .   .   .   .   .   .
  SHV-57                                      .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     R   .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .
  SHV-64                                      .                         .   .   .   .   .   .   Q     .   .     .   .   L   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   S   K   .   .   .   .   .   .   .
  SHV-66                                      .                         .   .   .   .   .   .   Q     .   .     .   Q   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   S   K   .   .   .   .   .   .   .
  SHV-70                                      .                         .   .   .   .   .   .   Q     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   V   .   .   .     .   .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .
  SHV-86                                      F                         .   .   .   .   .   .   Q     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   S   R   .   .   .   .   .   .   .
  SHV-90                                      .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     T   .   .   .   .   .   .   S   K   .   .   .   .   .   .   .
  SHV-91                                      .                         .   .   .   .   S   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   .   K   .   .   .   .   .   .   .
  SHV-98                                      .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   .   .   .   I   .   .   .   .   .
  SHV-99                                      .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   G   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .
  SHV-100                                     F                         .   .   .   .   .   .   Ins   .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .
  SHV-102                                     .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   A   .   .   .   .   .   .   .   .
  SHV-104                                     .                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   S   .   .   .   .   .   .   .   .   .   .
  SHV-105                                     .                         F   .   .   .   .   .   .     S   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   D   .     .   .   .     .   .   .   .   .   .   .   S   K   .   .   .   .   .   .   .
  SHV-106[^\*^](#TN5){ref-type="table-fn"}    F                         .   .   .   .   .   .   .     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   S   .   .   .   .   .   .   .   .
  SHV-115                                     .                         .   .   .   .   .   .   .     .   .     H   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   .   K   .   .   K   .   .   .   .
  SHV-128                                     .                         .   .   .   .   .   .   Q     .   .     .   .   .   .   .   .   .   .   .   R   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   S   K   .   .   .   .   .   T   P
  SHV-129                                     .                         .   .   .   .   .   .   Q     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   .     .   .   .   .   .   .   .   S   K   .   .   .   L   D   .   .
  SHV-134                                     .                         .   .   .   .   .   .   Q     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   E   .   .     .   .   .     .   .   .   .   .   .   .   S   K   .   .   .   .   .   .   .
  SHV-183                                     .                         .   .   .   .   .   .   Q     .   .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     .   .   Ins   .   .   .   .   .   .   .   S   K   .   .   .   .   .   .   .

*Amino acid numbering is according to SHV-1 (Ambler numbering system, upper row). Dots indicate identical amino acids*.

*Amino acid positions for SHV-16 (96, 97, 163), SHV-86 (7), SHV-100 (7, 35), SHV-106 (7, 8) and SHV-183 (186) have been updated from what reported in the Lahey Clinic Website (<http://www.lahey.org/studies/>) according to GenBank sequences: bla~SHV-16~, [AF072684.2](AF072684.2); bla~SHV-86~, [DQ328802](DQ328802); bla~SHV-100~, [AM941846](AM941846); bla~SHV-106~, [AM941847](AM941847); bla~SHV-183~, [HG934764](HG934764)*.

not confirmed as belonging to subgroup 2be;

*SHV-11 (Subgroup 2b) is provided as reference*.

Among SHV ESBLs, amino acid substitutions are predominantly located at positions Leu^35^, Gly^238^, and Glu^240^, while other less frequent but critical substitutions for the extended-spectrum phenotype occur on several amino acids including Ile^8^, Arg^43^, Glu^64^, Gly^156^, Asp^179^, and Arg^205^ (Table [2](#T2){ref-type="table"}). Although, most of these residues are not involved directly in β-lactams hydrolysis, they result in the enhancement or relaxation of the active site, enabling it to accommodate and to efficiently react with oxyimino-β-lactams (Tzouvelekis and Bonomo, [@B201]). Amino acid substitutions on some of these positions (Arg^43^, Asp^179^, Arg^205^, Gly^238^, and Glu^240^) have been also associated with the expansion toward an ESBL phenotype among TEM enzymes (Knox, [@B109]).

Residue Leu^35^ is located further away from the active site of class A β-lactamases and its substitution to Gln (e.g., SHV-2a, SHV-12) has been suggested to have an indirect role in enhancing the extended-spectrum capability of SHV β-lactamases (Nüesch-Inderbinen et al., [@B150]). In contrast, Gly^238^ and Glu^240^ amino acids are part of the active site lying near the R1 side chain of the β-lactam (Huletsky et al., [@B94]). Substitutions in Gly^238^ either to Ser (e.g., SHV-2, SHV-2a) or Ala (e.g., SHV-13, SHV-18) displace the β3-strand from the reactive Ser^70^, resulting in a slightly expanded active site. This conformational change improves the binding to and the accommodation of newer cephalosporins with large C7 substituents, thereby expanding the substrate spectrum of these SHV ESBLs to include cefotaxime and to a lesser extent to ceftazidime (Huletsky et al., [@B94]; Matagne et al., [@B130]; Nukaga et al., [@B152]). It has been suggested that Glu^240^ substitutions to Arg (SHV-86) or Lys (e.g., SHV-4, SHV-5) cause the ammonium group of the long side-chains of these residues to form an electrostatic bond with the carboxylic acid group on the oxyimino-substituents of ceftazidime and aztreonam (Knox, [@B109]). This interaction has a dual effect on the hydrolysis of ceftazidime by improving initial binding and facilitating proper positioning within the SHV β-lactamase, whereas the hydrolysis of other β-lactams is less affected (Huletsky et al., [@B94]). Gly^238^Ser and Glu^240^Lys amino acid substitutions characterize the majority of SHV ESBLs (Table [2](#T2){ref-type="table"}) and mirror those seen in extended-spectrum TEM β-lactamases. Interestingly, a plethora of extended-spectrum SHV and TEM β-lactamases exhibit higher levels of hydrolytic activity against ceftazidime than against cefotaxime (ceftazidimases) (Table [3](#T3){ref-type="table"}). This phenotype was attributed to the Glu^240^Lys substitution, in contrast with most CTX-M β-lactamases lacking this critical substitution and only showing a cefotaximase activity, (Bonnet, [@B24]).

###### 

**Kinetic parameters of available SHV-type extended-spectrum β-lactamases**.

  **Enzyme**                                                                   **Parameter**     **PEN**         **AMP**     **AMX**       **TIC**      **PIP**      **CER**   **CEF**       **CAZ**         **CTX**      **FEP**       **ATM**       **CLA**      **SUL**   **TZB**
  ---------------------------------------------------------------------------- ----------------- --------------- ----------- ------------- ------------ ------------ --------- ------------- --------------- ------------ ------------- ------------- ------------ --------- --------------
  SHV-1[^\*\*^](#TN7){ref-type="table-fn"}                                     *K*~cat~          455                         900           60           570          170       10            NH              NH           \>100         NH                                   
                                                                               *K*~m~            20                          90            22           60           110       26            ND              ND           \>3000        ND                                   
                                                                               *K*~cat~/*K*~m~   23,000                      10,000        2700         10,000       1500      400           ND              ND           \>35          ND                                   
                                                                               *V*~max~/*K*~m~   100                                                                 4         1                                                                                             
                                                                               *K*~i~                                                                                                                                                                 0.19         1.70      0.057
                                                                               IC~50~                                                                                                                                                                 0.057        7.50      0.150
  SHV-2                                                                        *K*~i~                                                                                                                                                                 0.16         0.36      0.04
                                                                               IC50                                                                                                                                                                   0.020        0.57      0.049
                                                                               *V*~max~          100                                                                                         6.5             70                         1                                    
                                                                               *K*~m~            3.5             12                                     ND                     ND            24              18           NA            10                                   
                                                                               *K*~cat~                          206                                    ND                     ND                            11           NA                                                 
                                                                               *K*~cat~/*K*~m~                   17                                     ND                     ND                            0.6          0.008                                              
  SHV-2a                                                                       *K*~i~                            13                                                            5             72              4                          3             0.08         0.47      0.027
                                                                               IC~50~                            100                                                           53            1               10                                       0.018        0.68      0.038
  SHV-4                                                                        *V*~max~          100                                                                                         52              115                        5                                    
                                                                               *K*~m~            3.5                                                                                         60              25                         0.5                                  
  SHV-5                                                                        *K*~i~                                                                                                                                                                 0.10         0.18      0.036
                                                                               IC50                                                                                                                                                                   0.005        0.40      0.022
                                                                               *K*~m~            15              11                                                            3             23              7                          0.02                                 
                                                                               *V*~max~/*K*~m~   100             100                                                           51            4               7                                                               
  SHV-7                                                                        *K*~m~                                                                                          2.7           24              11                         13                                   
                                                                               *V*~max~                                                                                        35            13              30                         3.3                                  
  SHV-9                                                                        *V*~max~          100             215                                                           58            10              24                                                              
                                                                               *K*~m~            18              12                                                            5             18              9                                                               
                                                                               IC50                                                                                                                                                                   0.14         0.43      
  SHV-13                                                                       *K*~m~            10              28                                     18                                   91              11                         77                                   
                                                                               *V*~max~          100             178                                    136                                  0.38            12                         0.66                                 
                                                                               *V*~max~/*K*~m~   100             64                                     76                                   0.42            11                         0.86                                 
  SHV-18                                                                       *V*~max~          100                                                                 200                     13.5            26.9                       \< 1                                 
                                                                               *V*~max~/*K*~m~   100                                                                 53                      1.5             24                         ND                                   
  SHV-24                                                                       *V*~max~                          2                                                   2.37                    0.043                                      0.735                                
                                                                               *K*~m~                            32                                                  210                     30                                         500                                  
                                                                               *V*~max~/*K*~m~                   0.0625                                              0.0113                  0.000143                                   0.00147                              
                                                                               *K~i~*                            57                                                  ND                      37                                         ND                                   
  SHV-38*[^\$^](#TN8){ref-type="table-fn"}*                                    *K*~cat~          100                         1800          10           100          40        5             110             1            3             3                                    
                                                                               *K*~m~            13                          35            14           80           150       100           3800            800          1600          5500                                 
                                                                               *K~cat~*/*K*~m~   7700                        51,000        700          1300         270       50            30              1            2             0.5                                  
  SHV-55[^\*^](#TN10){ref-type="table-fn"}                                     *K*~m~            5 ± 0.51                    10 ± 0.14     6 ± 0.02     8 ± 0.37               9 ± 0.68      58 ± 7.40       21 ± 0.13    149 ± 2.61    5 ± 0.62                             
                                                                               *K*~cat~          23 ± 0.76                   23 ± 0.17     8 ± 0.00     27 ± 1.53              38 ± 3.94     9 ± 0.21        24 ± 0.34    30 ± 3.10     \< 0.1                               
                                                                               *K~cat~*/*K*~m~   5.3 ± 0.42                  2.5 ± 0.002   1.5 ± 0.00   3.7 ± 0.03             4.4 ± 0.78    0.2 ± 0.02      1.1 ± 0.01   0.2 ± 0.02    ND                                   
                                                                               IC~50~                                                                                                                                                                 0.02                   
  SHV-57                                                                       *K*~m~            67                                                                                          30.9                                                                            
                                                                               *K*~cat~          3.8 × 10^−3^                                                                                8.6 × 10^−4^                                                                    
                                                                               *K*~cat~/*K*~m~   5.67 × 10−^5^                                                                               2.78 × 10−^5^                                                                   
                                                                               *K~i~*                                                                                                                                                                 27 × 10^3^             1.16 × 10^3^
  SHV-99[^\*^](#TN10){ref-type="table-fn"}                                     *K*~m~            12 ± 0.11                   11 ± 0.26     5 ± 0.93     13 ± 1.43              102 ± 11.38   136 ± 4.09      183 ± 0.72                 196 ± 0.60                           
                                                                               *K*~cat~          778 ± 616                   563 ± 8       58 ± 2       563 ± 13               37 ± 2        \< 0.1          \< 0.1                     0.5 ± 0.001                          
                                                                               *K*~cat~/*K*~m~   62.3 ± 4.4                  49.6 ± 1.8    13 ± 2.4     43.5 ± 6.5             0.37 ± 0.04   \< 0.001        \< 0.001                   0.003                                
                                                                               IC~50~                                                                                                                                                                 0.02                   0.03
  SHV-104                                                                      *K*~cat~          55                                        80                                  30                            \>1.8                                                           
                                                                               *K*~m~            94                                        10                                  68                            \>600                                                           
                                                                               *K*~cat~/*K*~m~   0.6                                       8                                   0.44                          0.003                                                           
  SHV-129[^\#^](#TN9){ref-type="table-fn"}[^\*^](#TN10){ref-type="table-fn"}   *K*~cat~                          22.8 ± 11                              1688 ± 4               26 ± 1        3.1 ± 1.5       4.8 ± 3.4    4.5 ± 0.5                                          
                                                                               *Km*                              46.8 ± 24                              25 ± 9                 12.1 ± 3.7    24 ± 3          26.7 ± 5.5   52 ± 3.5                                           
                                                                               *K*~cat~/*K*~m~                   0.5 ± 0.7                              7 ± 0.4                2.2 ± 0.3     0.13 ± 0.5      0.2 ± 0.5    0.09 ± 0.01                                        
                                                                               *K*~i~                                                                                                                                                                 0.4          0.4       0.04

*Antibiotic: Penicillin (PEN); Ampicillin (AMP); Amoxicillin (AMX); Ticarcillin (TIC); Piperacillin (PIP); Cephaloridine (CER); Cephalothin (CEF); Ceftazidime (CAZ); Cefotaxime (CTX); Cefepime (FEP); Aztreonam (ATM); Clavulanic Acid (CLA); Sulbactam (SUL); Tazobactam (TZB)*.

*Parameters are expressed as μM (K~i~, IC~50~, K~m~), s^−1^(K~cat~), and μM/min (K~cat~/K~m~, V~max~). Only antibiotics for which 3 or more SHV enzyme values were available are reported*.

*NA, not able to determine the rate of hydrolysis and affinity; NH, not hydrolyzed; ND, not determined*.

*Non ESBL SHV-1 is provided as reference*.

*K~cat~/K~m~ values are expressed as mM/s*.

*K~cat~/K~m~ values are expressed as μM/s*.

*Values (Except IC~50~) represent mean ± standard deviation*.

*References: SHV-1 (Gutmann et al., [@B75]; Poirel et al., [@B165]); SHV-2 (Gutmann et al., [@B75]; Bradford et al., [@B29]; Winkler and Bonomo, [@B213]); SHV-2a (Podbielski et al., [@B164]); SHV-4 (Péduzzi et al., [@B158]); SHV-5 (Gutmann et al., [@B75]); SHV-7 (Bradford et al., [@B29]); SHV-9 (Prinarakis et al., [@B170]); SHV-13 (Yuan et al., [@B217]); SHV-18 (Rasheed et al., [@B174]); SHV-24 (Kurokawa et al., [@B110]); SHV-38 (Poirel et al., [@B165]); SHV-55 (Mendonça et al., [@B134]); SHV-57 (Ma et al., [@B120]): SHV-99 (Ramdani-Bouguessa et al., [@B171]); SHV-104 (Ben Achour et al., [@B20]); SHV-129 (Winkler and Bonomo, [@B213])*.

Among the less frequent but critical substitutions, Ile^8^Phe in the signal sequence of the precursor of SHV ESBLs (e.g., SHV-7, SHV-18) has been associated with a more efficient β-lactamase transfer into the periplasm (Randegger et al., [@B173]), a proof that, beside enzymatic structure and gene expression, also the rate of transfer plays a role in resistance phenotype. On the contrary, Arg^43^Ser (e.g., SHV-7, SHV-18) and Gly^156^Asp (SHV-27, SHV-45, SHV-105) substitutions affect the structural arrangement of the conserved residues 64--69 and 166--170, respectively. These changes, opposite to the active site cavity (Ser^70^) for the hydrolysis of the β-lactam molecules, expand the active site to accommodate bulkier cephalosporins (Knox, [@B109]; Corkill et al., [@B49]). Asp^179^ amino acid is highly conserved among subclass A1 of serine β-lactamases and together with Arg^164^ form a salt bridge that links the two ends of the Ω loop. Substitutions Asp^179^Ala (SHV-6), Asp^179^Asn (SHV-8) and Asp^179^Gly (SHV-24) result in the elimination of the salt bridge with subsequent increase in ceftazidime resistance (Sowek et al., [@B189]). Several other amino acid substitutions (Table [2](#T2){ref-type="table"}) have been described as either responsible for or possibly contributing to the ESBL phenotype, the detailed description of which exceeds the scope of this review.

Apart from point mutations leading to amino acid substitutions, frame shift mutations have been observed with very low occurrence among SHV ESBLs resulting in amino acid insertions (Arpin et al., [@B16]; Ramdani-Bouguessa et al., [@B171]) or deletions (Prinarakis et al., [@B170]). However, their role in the rising of the extended-spectrum phenotype remains unclear. SHV ESBL variants falling in this category are: (i) SHV-9, with the deletion of Gly^54^ (Prinarakis et al., [@B170]); (ii) SHV-16, with a 5-amino acid sequence duplication (Asp^163a^ArgGluTrpGluThr-Asp^163b^ArgGluTrpGluThr) of the amino acids between 163 and 167, including Glu^166^ in the Ω loop (Arpin et al., [@B16]); (iii) SHV-100, with a 13-amino acid insertion (SerGluSerGlnLeuSerGlyArgValGlyMetIleGlu) between amino acids 35 and 36 (Ramdani-Bouguessa et al., [@B171]); and (iv) SHV-183, with an Ala insertion between amino acids 186 and 187 (<http://www.lahey.org/studies>). Of note, the duplication observed in SHV-16 was shown to increase the conformational flexibility of the catalytic region facilitating the access of bulkier cephalosporins, such as ceftazidime, but resulted in enzymatic instability (Arpin et al., [@B16]). This finding could explain the low incidence of frame shift mutations among extended-spectrum SHV β-lactamases, due to a deleterious effect on the enzymes.

Overall, the available SHV ESBL kinetic parameters show that most of the substitutions lead to more efficient hydrolysis of oxyimino-β-lactams than penicillins, as depicted by the low K~*cat*~ values for penicillins (Table [3](#T3){ref-type="table"}). While they retain their ability to hydrolyze penicillins, they are not catalytically so efficient compared to SHV-1 (Bush and Singer, [@B34]) and this is due to the decreased strength of the crucial hydrogen-bonding network needed for penicillin catalysis (turnover). As a consequence, since β-lactam inhibitors (clavulanic acid, sulbactam, and tazobactam) are structurally very similar to penicillin substrates, SHV ESBLs also exhibit increased susceptibility to β-lactam inhibitors compared to SHV-1 (Table [3](#T3){ref-type="table"}) leading to less inhibitor required for inactivation (lower K~i~ and IC~50~s; Tzouvelekis and Bonomo, [@B201]).

Detection {#s4}
=========

There are at least 46 known SHV-ESBL genes together with more than 150 non-ESBL or unclassified alleles to date (<http://www.lahey.org/studies/>). Accurate identification of these variants is essential for surveillance and for epidemiological studies of transmission mode, particularly in clinical setting, where appropriate antimicrobial therapy is critical.

A panel of different phenotypic confirmatory tests is available to determine the presence of extended-spectrum β-lactamases, including SHV-variants: minimum inhibitory concentration (MIC) determination of β-lactam with and without clavulanic acid, double disk synergy test (DDST), inhibitor potentiated disk diffusion test (IPDDT), three-dimensional test (TDT) and commercially available methods (Etest for ESBLs, Vitek ESBL cards, MicroScan panels, and BD Phoenix Automated Microbiology System (Bradford, [@B28]; Paterson and Bonomo, [@B157]). Standard microbiological procedures can take up to several days for culture, isolation and characterization and many comparative studies have shown that PCR-based methods have higher sensitivity (Bedenic et al., [@B18], [@B19]; Singh et al., [@B185]), mostly due to variable levels of gene expression. Therefore, PCR and nucleotide sequence analysis (Stürenburg et al., [@B192]), together with various PCR-based methods, remain the gold standard for extended-spectrum β-lactamase SHV-variants identification.

Chanawong and colleagues developed a PCR-restriction fragment length polymorphism (PCR-RFLP) method to allow the identification of new SHV β-lactamases variants through detection of known mutations that alter recognition sites of restriction endonucleases (Chanawong et al., [@B43]). PCR-RFLP complements pre-existing PCR-single strand conformational polymorphism (PCR-SSCP) limited by partial gene amplification, thus missing potential mutation sites (M\'Zali et al., [@B141]). PCR-RFLP can also be used in combination with restriction site insertion-PCR (RSI-PCR), a method based on primers mismatches, allowing the unambiguous identification of up to 27 SHV variants by point mutation (Chanawong et al., [@B44]). Fluorescently labeled hybridization probes followed by melting curve analysis can also be used to discriminate between ESBL and non-ESBL *bla*~SHV~ genes (Randegger and Hächler, [@B172]). This method, termed the SHV melting curve mutation detection method, is also able to categorize SHV ESBL producers into phenotypically relevant subgroups: (i) weak ceftazidime resistance (SHV-6 and SHV-8); (ii) significant resistance to cefotaxime and ceftriaxone and moderate resistance to ceftazidime (SHV-2, SHV-2a, and SHV-3); and (iii), most effective against all expanded-spectrum cephalosporins (SHV-4, SHV-5, SHV-9, and SHV-12). Combined systems can also be developed *ad hoc* to rapidly screen local epidemiological settings (Chia et al., [@B48]). A modified SHV melting-curve mutation detection method able to distinguish between prevalent Taiwanese *bla*~SHV~ genes (SHV-1, SHV-2, SHV-2a, SHV-5, SHV-11, and SHV-12) was combined with a multiplex PCR to identify different β-lactamases genes (*bla*~SHV~, *bla*~CTX-*M*-3~-like, and *bla*~CTX-*M*-14~). The design of this method can be easily adapted to other geographic areas where different ESBLs are prevalent. Multiplex real-time PCR assays for the fast detection of extended-spectrum β-lactamase and carbapenemase genes were developed with differential melting curves able to recognize up to 120 different SHV allelic variants (Singh et al., [@B186]).

New techniques for ESBL detection are employed alongside PCR-based methods these days. Loop-mediated isothermal amplification (LAMP) was applied to detect SHV- and other ESBL-producing bacteria in meat and proved to be more specific and sensitive than MacConkey agar or cefpodoxime disc methods (Anjum et al., [@B10]). Commercial DNA microarrays are also proving themselves to be accurate, with sensitivity and specificity values for ESBL detection being high. Up to 53 SHV-variants can be covered on a same array (Leinberger et al., [@B115]), but on the other hand some alleles may fail to be detected (i.e., SHV-12), as previously reported (Stuart et al., [@B191]). Because arrays have major limitations to detect novel genes or variants, PCR and sequencing remains essential. Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MS) is routinely used for bacteria identification and has been recently applied to detect ESBL-producing Enterobacteriaceae from positive blood cultures in clinical practice (Jung et al., [@B103]; Oviaño et al., [@B155]). Although, this methodology has yet to be fully validated, preliminary results show 99% sensitivity and 100% specificity, and denote a novel approach to categorize bacteria as ESBL producers.

Pyrosequencing combines standard PCR and sequencing by synthesis to rapidly determine the sequence of a target DNA region; it has been extensively used for the detection of bacterial resistance genes and bacterial community composition (Tang et al., [@B195]; Tian et al., [@B198]). This technique has been used to perform mutation analysis of *bla*~SHV~ to resolve heterogeneous sequences in clinical isolates of *K. pneumoniae* containing more than one SHV variant (Haanperä et al., [@B76]). An alternative protocol for pyrosequencing is the single-nucleotide polymorphism (SNP), ideal for the sequencing of mixed templates and determination of SNPs at the position of interest. This protocol has been applied to discriminate between eight *bla*~SHV~ variants from clinical isolates of *E. coli* and *K. pneumoniae*, reporting great reproducibility and ability to discriminate between sequences (Jones et al., [@B99]). A multiplex pyrosequencing assay coupled with qPCR amplification has also been recently developed to enable rapid and accurate detection of *bla*~SHV~ and *bla*~TEM~ -producing Enterobacteriaceae (Deccache et al., [@B52]). Overall, pyrosequencing can be a useful epidemiological tool for the exact identification of *bla*~SHV~ as a prerequisite for analyzing the spread of certain SHV variants.

Finally, the advent of whole genome sequencing (WGS) has taken differentiation of bacterial strains and identification of the associated antibiotic resistance gene cargo to another level. Aside from the phylogenetic analysis that WGS provides, the complete resistome of a strain can be unraveled as well as its mobilome, i.e., the mobile genetic elements that are associated with antibiotic resistance diffusion. Only this information can provide us with full understanding of complex genomic structures as observed, for example, in clinical *K. pneumoniae* genomes carrying (i) nineteen antibiotic resistance genes including *bla*~OXA-1~ and *bla*~SHV-28~ in the chromosome, *bla*~NDM-1~ in a plasmid, and *bla*~OXA-232~ in a second plasmid (Kwon et al., [@B111]); (ii) β-lactamase genes *bla*~KPC−2~, *bla*~SHV-11~, *bla*~TEM−169~, and *bla*~OXA-9~, together with *aac(6*′-)*Ib, aadA2*, and *aph(3*′-*)Ia* as aminoglycoside resistance encoding genes, *mph(A)* for macrolides, *oqxA* and *oqxB* for quinolone, *catA1* for phenicol, *sul1* for sulfonamide, and *dfrA12* for trimethoprim (Lee et al., [@B114]); or (iii) six different plasmids, adding up to 0.43 Mbp, coding for six β-lactamases (*bla*~SHV-12~, *bla*~OXA-9~, *bla*~TEM-1~, *bla*~CTX-*M*-2~, and *bla*~KPC−2~), together with *bla*~SHV-110~ and adhesin-related gene clusters on the chromosome (Perreira Ramos et al., [@B159]).

Expansion toward new ecological niches {#s5}
======================================

Over the last years the presence of antibiotics as well as antibiotic resistant bacteria has been shown outside the clinical environment, including water, soil and, most notably, food producing animals. When looking at SHV-variants distribution it is evident that in recent years, as for most extended-spectrum β-lactamases (Canton et al., [@B38]), their presence has been confirmed in virtually all ecological niches (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}), making it more challenging to restrain antibiotic resistance diffusion. The most representative cases and variants will be discussed.

Aquatic environment
-------------------

In an effort to control the release of antibiotics and antibiotic resistant bacteria in the environment, aquatic environments are being investigated worldwide, whether they be natural, drinking or wastewaters. The latter are particularly worrisome given the high prevalence of *bla*~SHV~ alleles, as observed in untreated hospital wastewater in Australia (Gündogdu et al., [@B74]), their possible association with determinants of quinolone and other β-lactamase resistance (Calhau et al., [@B37]; Osinska et al., [@B154]), and their relatively easy transmission to surface water through waste water treatment plant discharges (Marti et al., [@B129]). Studies showed that SHV types, together with CTX-M and OXA genes can be significantly decreased by biological treatments such as activated sludge processing and anaerobic digestion, although not all can be effectively eliminated (Yi et al., [@B215]).

Urban waters are also exposed to relatively high population densities and therefore are often unprotected from biological contaminants, with people playing a crucial role in antibiotic resistance dissemination in the environment. Unusual finding of SHV-producing *Stenotrophomonas maltophilia* in a swimming recreational Serbian lake and its transient presence during summer months can be considered as a proof of its anthropogenic origin, given its nature of emerging nosocomial pathogen (Novovic et al., [@B149]). Similar conclusions can be drawn for SHV-producing *K. pneumoniae* and *E. cloacae* isolated from a Bangladeshi lake, which receives waste water from surrounding residents, commercial buildings and clinics in Dhaka city (Haque et al., [@B81]), as well as for artificial water reservoirs in Poland (Wolny-Koladka and Lenart-Boron, [@B214]), or urban surface waters in Malaysia (Tissera and Lee, [@B200]). In recent surveillance studies of different rivers and lakes in Switzerland, *bla*~SHV-12~-producing Enterobacteriaceae were isolated only in 4% of the cases (Zurfluh et al., [@B222]), although this variant is predominant in clinical Swiss isolates (Nüesch-Inderbinen et al., [@B150]). *bla*~SHV-12~ was also detected in Enterobacteriaceae from seawater, together with *tet(A)* and *sul2* in Portugal (Alves et al., [@B8]), and plasmid-encoded together with *bla*~TEM-1~ and/or *bla*~CTX-*M*-1~ in Croatia (Maravic et al., [@B125]). Finally, data on ESBL-producing Enterobacteriaceae isolated from drinking water is also increasing, reporting SHV alleles in rural water reservoirs in China (Zhang et al., [@B218]), or drinking water sources for First Nation communities in Canada (Fernando et al., [@B70]).

Food producing animals
----------------------

Food producing animals have become subject of increasing interest after several studies demonstrated that resistant strains of animal origin can be associated to human infections, possibly through the food chain (Hasman et al., [@B84]). Majority of SHV variants in this reservoir belong to *bla*~SHV-2~, *bla*~SHV-2*a*~, *bla*~SHV-5~, and *bla*~SHV-12~ (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}) owing to their successful association with conjugative plasmids (see Section Plasmid epidemiology of *bla*~SHV-2~, *bla*~SHV-2*a*~, *bla*~SHV-5~, and *bla*~SHV-12~).

Surveillance activities in healthy animals worldwide are generating a tremendous amount of data on ESBL distribution. Most SHV β-lactamase producers are *E. coli* from swine and broiler fecal samples as observed in China (Tian et al., [@B197]); in Spain, with *bla*~SHV-2~ associated with *bla*~CTX-*M*-9~ and *bla*~SHV-12~ with *bla*~CTX-*M*-1~, in pigs and broilers respectively (Blanc et al., [@B23]); in layers, cattle, and broilers but not in swine in Japan (Hiki et al., [@B88]; Kameyama et al., [@B104]); and in the Netherlands, where healthy broilers carried *bla*~SHV-2~ in combination with *bla*~TEM-1~ or *bla*~TEM−135~ (Dierikx et al., [@B55]). Other Enterobacteriaceae like *K. pneumoniae* and *Citrobacter freundii* were positive for *bla*~SHV-2~ or *bla*~SHV-12~ from poultry and swine, respectively (Machado et al., [@B122]).

Finding ESBL producers in food producing animals is also mirrored by positive food samples worldwide, mostly retail chicken meat, as reported in Tunisia, with *E. coli* carrying *bla*~SHV-5~ isolated from different butcheries, supermarkets, and local markets (Jouini et al., [@B102]), or *Salmonella enterica* carrying *bla*~SHV-12~ in Japan (Noda et al., [@B148]). The cross-contamination between food producing animals and retail meat has been internationally demonstrated due to the detection of plasmid-borne SHV variants, such as *bla*~SHV-2~ and *bla*~SHV-2*a*~ from Canadian chicken meat and abattoir chicken cecum (Pouget et al., [@B168]) or *bla*~SHV-2~ and *bla*~TEM-1~ in Japan (Hiroi et al., [@B89]), presenting the potential for horizontal transfer between Enterobacteriaceae as a high public health concern.

SHV β-lactamase producing Enterobacteriaceae have been detected also in diseased animals, as reported for septicemic broilers due to avian pathogenic *E. coli* encoding a remarkable array of antibiotic resistance genes (*dfrA17-aadA5, bla*~TEM-1~, *bla*~CTX-*M*-15~, *bla*~OXA-1~, *bla*~SHV-2~, *tet*(A), *tet*(E), *qnrB2, aac*(6)-Ib-cr) (Ahmed et al., [@B4]); for *K. pneumoniae* isolated from bovine mastitis in the United Kingdom (Timofte et al., [@B199]) and Egypt (Ahmed and Shimamoto, [@B3]); and for multidrug resistant *S. enterica* serotypes Enteritidis and Typhimurium isolated from diarrheic calves (Ahmed et al., [@B5]).

Finally, *bla*~SHV-27~ is the only other SHV variant frequently reported as chromosomally located in *K. pneumoniae* from swine, in association with *bla*~SHV-11~ and *bla*~CTX-*M*-1~ in China (Zou et al., [@B220]); in *E. coli* isolated from farmed fish together with non ESBLs *bla*~SHV-1~, *bla*~SHV-11~, *bla*~SHV-25~, and *bla*~SHV-26~ (Jiang et al., [@B97]); and in opportunistic pathogens asymptomatically colonizing healthy milk cows (Hammad and Shimamoto, [@B79]).

Wildlife, companion animals, and vegetables
-------------------------------------------

ESBL diffusion has been studied extensively in Enterobacteriaceae from humans and livestock, whereas information on antibiotic resistance in the environment is still limited. Yet, the dissemination success of *bla*~SHV-12~ is confirmed by its introduction into the wildlife, notably in birds, as reported in Spain (Alcalá et al., [@B6]), the Netherlands (Veldman et al., [@B204]), Poland (Literak et al., [@B117]), and the Czech Republic (Dolejská et al., [@B57]). This success is likely associated to predominant avian clones and to efficient plasmids (Table [4](#T4){ref-type="table"}, **Figure 3**) of the IncN incompatibility group, described to be more frequent in pathogenic than in commensal avian and human *E. coli* strains (Johnson et al., [@B98]). *bla*~SHV-5~ was also detected in *E. coli* from several birds of prey in Portugal, alone or in associations with *bla*~TEM−1b~ (Pinto et al., [@B161]).

###### 

**Plasmid epidemiology of SHV-type extended-spectrum β-lactamases**.

  **Inc Group**        **Plasmid Size (Kb)[^\*^](#TN11){ref-type="table-fn"}**   ***bla*~SHV~ allele[^§^](#TN12){ref-type="table-fn"}**   **Other Antibiotic Resistance Genes**                                                                **Bacterial Species[^\#^](#TN13){ref-type="table-fn"}**               **Country**         **References**
  -------------------- --------------------------------------------------------- -------------------------------------------------------- ---------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- ------------------- ----------------------------------
  IncA/C               ND (C)                                                    SHV-12 or SHV-2a                                         ND                                                                                                   *E. coli* (H)                                                         Tunisia             Mnif et al., [@B137]
                       150 (C)                                                   SHV-12                                                   *bla*~VIM−1~, *aac(6′)-Ib\', aadA1b, catB2, sul1, dfrA14*                                            *A. caviae* (H)                                                       Italy               Antonelli et al., [@B11]
                       150 (NC)                                                  SHV-12 (IS*26*)                                          *bla*~CTX-M-14~, *bla*~*DHA*−1~                                                                      *P. mirabilis* (H)                                                    Korea               Song et al., [@B187]
                       ND                                                        SHV-2, SHV-5 or SHV-12                                   ND                                                                                                   *E. coli* (H)                                                         France              Marcadé et al., [@B127]
                       130 (C)                                                   SHV-5 (IS*26*)                                           *bla*~*VEB*−1~, *bla*~VIM−1~, *aacA7, dfrA1, aadA1, bla*~OXA-1~, *bla*~TEM-1~, *aadB, arr2, cmlA5*   *P. stuartii* (H)                                                     Greece              Giakkoupi et al., [@B73]
                       97--145                                                   SHV-45                                                   *bla*~CTX-M-2~; *bla*~SHV-27~                                                                        *K. pneumoniae* (H)                                                   Brazil              Dropa et al., [@B59]
                       63.5--209                                                 SHV-55                                                   *bla*~CTX-M-2~; *bla*~SHV-28~                                                                        *K. pneumoniae* (H)                                                   Brazil              Dropa et al., [@B59]
  IncA/C-IncR          220 (C)                                                   SHV-5                                                    *bla*~VEB−1~, *bla*~VIM−1~*, rmtB, aacA7, dfrA1, aadA1*                                              *P. stuartii* (H)                                                     Greece              Oikonomou et al., [@B153]
  IncF                 125                                                       SHV-5 (IS*26*)                                           ND                                                                                                   *E. coli* (H)                                                         Poland              Zienkiewicz et al., [@B219]
  IncFIA-FIB           ND (C)                                                    SHV-12                                                   ND                                                                                                   *E. coli* (H)                                                         Tunisia             Mnif et al., [@B137]
  IncFIB               ND                                                        SHV-12                                                   *sul3*                                                                                               *E. coli* (A)                                                         Italy               Bortolaia et al., [@B25]
                       95--200 (C)                                               SHV-2                                                    *aadA1*                                                                                              *E. coli* (A)                                                         Canada              Pouget et al., [@B168]
                       \>23                                                      SHV-2                                                    ND                                                                                                   *K. pneumoniae* (H)                                                   China               Wang et al., [@B210]
                       ND                                                        SHV-2                                                    ND                                                                                                   *E. coli* (H)                                                         France              Marcadé et al., [@B127]
                       ND (C)                                                    SHV-5                                                    \-                                                                                                   *E. coli* (H)                                                         Uruguay             
  IncFIB10             ND                                                        SHV-12 (IS*26*)                                          *bla*~TEM-1~                                                                                         *E. coli* (H)                                                         UK                  Doumith et al., [@B58]
  IncFIC               ND                                                        SHV-5                                                    *aac(6′)-Ib\', aadA1*                                                                                *S. marcescens* (H)                                                   Uruguay             García-Fulgueiras et al., [@B72]
  IncF-N               ND                                                        SHV-2                                                    *aac(6′)-Ib\'*                                                                                       *K. pneumoniae* (H)                                                   Uruguay             García-Fulgueiras et al., [@B72]
  IncFII               ND                                                        SHV-2 or SHV-12                                          ND                                                                                                   *E. coli* (H)                                                         France              Marcadé et al., [@B127]
                       70--80 (C)                                                SHV-2a (IS*26*)                                          ND                                                                                                   *K. pneumoniae* (H)                                                   Tunisia             Elhani et al., [@B63]
                       100 (C)                                                   SHV-128 (IS*26*)                                         ND                                                                                                   *E. cloacae* (H)                                                      Tunisia             Bourouis et al., [@B27]
  IncFII-FIA           ND (C)                                                    SHV-12                                                   ND                                                                                                   *E. coli* (H)                                                         Tunisia             Mnif et al., [@B137]
  IncFII-FIA-FIB       ND (C)                                                    SHV-12                                                   ND                                                                                                   *E. coli* (H)                                                         Tunisia             Mnif et al., [@B137]
  IncFII-FIB           ND                                                        SHV-2                                                    ND                                                                                                   *E. coli* (H)                                                         France              Marcadé et al., [@B127]
                       ND (C)                                                    SHV-2a                                                   ND                                                                                                   *E. coli* (H)                                                         Tunisia             Mnif et al., [@B137]
  IncFIIk1             200--220                                                  SHV-2, SHV-55 or SHV-106                                 ND                                                                                                   *K. pneumoniae* (H)                                                   Portugal            Rodrigues et al., [@B178]
  IncFIIk5             220                                                       SHV-55                                                   ND                                                                                                   *K. pneumoniae* (H)                                                   Portugal            Rodrigues et al., [@B178]
  IncHI2               ND (C)                                                    SHV-2a or SHV-12                                         ND                                                                                                   *E. coli* (H)                                                         Tunisia             Mnif et al., [@B137]
                       95 (C)                                                    SHV-12 (IS*26*)                                          ND                                                                                                   *K. pneumoniae* (H)                                                   Tunisia             Elhani et al., [@B63]
                       310 (C)                                                   SHV-12                                                   *qnrB2, bla~TEM-1~*, *sul1, dfrA19, tet(D), strA, strB, aac(60)-1b*                                  *S*. Senftenberg (H)                                                  Netherlands         Veldman et al., [@B203]
                       200 (NC)                                                  SHV-12                                                   *tet(D)*                                                                                             *S*. Concord (H)                                                      Netherlands         Veldman et al., [@B203]
                       290 (C)                                                   SHV-12                                                   *qnrB2, bla*~TEM−1~, *sul1, sul2, dfrA19, tet(D), strA, strB*,                                       *S*. Concord (H)                                                      Netherlands         Veldman et al., [@B203]
                       180, 350, 380                                             SHV-12                                                   ND                                                                                                   *K. pneumoniae* (H)                                                   Portugal            Rodrigues et al., [@B178]
                       400                                                       SHV-12                                                   ND                                                                                                   *E. cloacae* (H)                                                      Portugal            Rodrigues et al., [@B178]
                       320 (C)                                                   SHV-12                                                   *qnrB2, strA/B, tet(D), clmA, sul1*                                                                  *S*. Bredeney (H)                                                     Spain               Herrera-Leon et al., [@B87]
                       ND (C)                                                    SHV-12 (IS*26*)                                          *bla*~CTX-M-14~                                                                                      *E. cloacae* (H)                                                      Taiwan              Chen C. M. et al., [@B46]
                       ND (C)                                                    SHV-12 (IS*26*)                                          *bla*~CTX-M-3~                                                                                       *E. cloacae*(H)                                                       Taiwan              Chen C. M. et al., [@B46]
  IncHI2 (ST1)         300 (C)                                                   SHV-2                                                    ND                                                                                                   *S*. Agona or Keurmassar (H)                                          Senegal             Harrois et al., [@B83]
  IncI1                ND (C)                                                    SHV-12                                                   ND                                                                                                   *E. coli* (H)                                                         Bulgaria            Markovska et al., [@B128]
                       ND                                                        SHV-12                                                   ND                                                                                                   *E. coli* (H)                                                         France              Marcadé et al., [@B127]
                       ND                                                        SHV-12                                                   *sul3*                                                                                               *E. coli* (A)                                                         Italy               Bortolaia et al., [@B25]
                       19 (C)                                                    SHV-12                                                   --                                                                                                   *E. coli* (A)                                                         Italy               Bortolaia et al., [@B26]
                       340 (C)                                                   SHV-12                                                   ND                                                                                                   *S*. Concord (H)                                                      Norway (Ethiopia)   Fabre et al., [@B68]
                       95 (C)                                                    SHV-12                                                   --                                                                                                   *E. coli* (A)                                                         Poland              Literak et al., [@B117]
                       10 (NC)                                                   SHV-12                                                   --                                                                                                   *S. enteritidis* (H)                                                  Spain               de Toro et al., [@B53]
                       60 (C)                                                    SHV-12                                                   *bla*~VIM−1~*-aacA4-dfrII- aadA1-catB2*                                                              *K. pneumoniae, E. coli* (H)                                          Spain               Tato et al., [@B196]
                       ND (C)                                                    SHV-12 (IS*26*)                                          *bla*~CTX-M-3~                                                                                       *E. cloacae* (H)                                                      Taiwan              Chen C. M. et al., [@B46]
                       95--200 (C)                                               SHV-2                                                    *aadA1*                                                                                              *E. coli, S*. Heidelberg (A)                                          Canada              Pouget et al., [@B168]
                       95--200 (C)                                               SHV-2                                                    --                                                                                                   *E. coli* (A)                                                         Canada              Pouget et al., [@B168]
                       95--200 (C)                                               SHV-2a                                                   *aadA1, dfrA1*                                                                                       *E. coli, S*. Kiambu (A)                                              Canada              Pouget et al., [@B168]
                       95--200 (C)                                               SHV-2a                                                   *aadA1*                                                                                              *E. coli* (A)                                                         Canada              Pouget et al., [@B168]
  IncI1 (ST26)         ND                                                        SHV-12                                                   ND                                                                                                   *E. coli* (H)                                                         Italy               Accogli et al., [@B2]
                       ND                                                        SHV-12 (IS*26*)                                          ND                                                                                                   *E. coli* (A)                                                         Portugal            Jones-Dias et al., [@B100]
  IncI1 (ST27, CC26)   115 (C)                                                   SHV-2                                                    *aadA2*                                                                                              *S*. Livingstone (H)                                                  Spain               de Toro et al., [@B53]
  IncI1 (ST29/CC26)    ND (C)                                                    SHV-12 (IS*26*)                                          ND                                                                                                   *E. coli* (E)                                                         Portugal            Jones-Dias et al., [@B100]
  IncI1 (ST3)          ND                                                        SHV-12                                                   ND                                                                                                   *E. coli* (A)                                                         Italy               Accogli et al., [@B2]
                       104 (C)                                                   SHV-12                                                   \-                                                                                                   *E. coli* (A)                                                         Italy               Bortolaia et al., [@B26]
  IncK                 ND (NC)                                                   SHV-12                                                   ND                                                                                                   *K. pneumoniae* (A)                                                   England             Timofte et al., [@B199]
                       155                                                       SHV-2                                                    --                                                                                                   *E. coli* (A)                                                         Netherlands         Dierikx et al., [@B55]
  IncL/M               ND (C)                                                    SHV-12                                                   ND                                                                                                   *E. coli* (H)                                                         Tunisia             Mnif et al., [@B137]
                       65                                                        SHV-12                                                   *bla*~KPC−2~, *rmtB*                                                                                 *K. pneumoniae* (H)                                                   China               Liu et al., [@B119]
                       65                                                        SHV-2                                                    ND                                                                                                   *K. pneumoniae* (H)                                                   Portugal            Rodrigues et al., [@B178]
                       ND (C)                                                    SHV-2a                                                   ND                                                                                                   *E. coli* (H)                                                         Tunisia             Mnif et al., [@B137]
                       60--70 (C)                                                SHV-2a (IS*26*)                                          ND                                                                                                   *K. pneumoniae* (H)                                                   Tunisia             Elhani et al., [@B63]
                       ND (C)                                                    SHV-5 (IS*26*)                                           *aacA4, aacC1, aadA1, sul1*                                                                          *S*. Typhimurium (H)                                                  Italy               Villa et al., [@B205]
                       90 (C)                                                    SHV-5                                                    *tet(A), aadA1, aacC1, aacA4, dfrA1*                                                                 *K. oxytoca* (H)                                                      USA                 Preston et al., [@B169]
  IncN                 ND (C)                                                    SHV-12                                                   ND                                                                                                   *E. coli* (H)                                                         Tunisia             Mnif et al., [@B137]
                       ND (C)                                                    SHV-12                                                   ND                                                                                                   *K. pneumoniae* (H)                                                   Bulgaria            Markovska et al., [@B128]
                       50                                                        SHV-12                                                   *bla*~VIM−1~, *qnrS*                                                                                 *K. pneumoniae, E. coli* (H)                                          Norway              Naseer et al., [@B145]
                       50 (C)                                                    SHV-12                                                   *bla*~VIM−1~, *qnrS*                                                                                 *K. pneumoniae* (H)                                                   Norway              Samuelsen et al., [@B181]
                       \>23                                                      SHV-2 (IS*26*)                                           ND                                                                                                   *K. pneumoniae* (H)                                                   China               Wang et al., [@B210]
                       ND (C)                                                    SHV-2a                                                   ND                                                                                                   *E. coli* (H)                                                         Tunisia             Mnif et al., [@B137]
  IncN (ST1)           ND                                                        SHV-12                                                   *aadA2*                                                                                              *E. coli* (H)                                                         Netherlands         Dierikx et al., [@B54]
  IncN (ST16)          50 (C)                                                    SHV-2                                                    ND                                                                                                   *S*. Miami (U)                                                        Senegal             Harrois et al., [@B83]
  IncP                 ND (C)                                                    SHV-12 (IS*26*)                                          --                                                                                                   *E. cloacae* (H)                                                      Taiwan              Chen C. M. et al., [@B46]
                       95--200 (C)                                               SHV-2a                                                   *aadA1, dfrA1*                                                                                       *E. coli* (A)                                                         Canada              Pouget et al., [@B168]
  IncX3                50 (C)                                                    SHV-12                                                   *bla*~KPC−2~                                                                                         *K. pneumoniae* (H)                                                   Australia           Partridge et al., [@B156]
                       54 (C)                                                    SHV-12                                                   *bla*~NDM-1~                                                                                         *K. pneumoniae* (H)                                                   China               Wang et al., [@B209]
                       54 (C)                                                    SHV-12 (IS*26*)                                          *bla*~NDM-1~                                                                                         *K. pneumoniae, C. freundii, E. aerogenes, E. cloacae, E. coli* (H)   China               Ho et al., [@B90]
                       60 (C)                                                    SHV-12                                                   *bla*~NDM-1~, *bla*~TEM-1~                                                                           *E. coli* (H)                                                         China               Huang et al., [@B93]
                       60 (C)                                                    SHV-12                                                   *bla*~NDM-1~                                                                                         *E. coli* (H)                                                         China               Huang et al., [@B93]
                       54 (C)                                                    SHV-12 (IS*26*)                                          *bla*~NDM-1~                                                                                         *E. coli* (H)                                                         China               Feng et al., [@B69]
                       54 (C)                                                    SHV-12 (IS*26*)                                          *bla*~NDM−1~                                                                                         *C. freundii* (H)                                                     China               Du et al., [@B60]
                       50                                                        SHV-12                                                   *qnrB7*                                                                                              *E. coli* (A)                                                         Czech Republic      Dobiasova and Dolejska, [@B56]
                       40                                                        SHV-12                                                   *qnrS1*                                                                                              *E. coli* (E)                                                         Czech Republic      Dobiasova and Dolejska, [@B56]
                       53                                                        SHV-12 (IS*26*)                                          *bla*~KPC−2~                                                                                         *K. pneumoniae* (H)                                                   France              Kassis-Chikhani et al., [@B105]
                       50 (C)                                                    SHV-12                                                   *bla*~NDM-1~                                                                                         *E. cloacae* (H)                                                      UAE                 Sonnevend et al., [@B188]
                       50 (C)                                                    SHV-12                                                   *bla*~NDM-1~                                                                                         *E. coli* (H)                                                         UAE                 Sonnevend et al., [@B188]
                       50 (C)                                                    SHV-12                                                   *bla*~NDM-1~                                                                                         *C. freundii* (H)                                                     UAE                 Sonnevend et al., [@B188]
                       43 (C)                                                    SHV-12 (IS*26*)                                          \-                                                                                                   *E. cloacae* (H)                                                      USA                 Hargreaves et al., [@B82]
  IncX3-N              80                                                        SHV-12                                                   *bla*~TEM-1~, *qnrS1*                                                                                *E. coli* (A)                                                         Germany             Dobiasova and Dolejska, [@B56]
  ColETp               10 (NC)                                                   SHV-12                                                   *qnrS1*                                                                                              *S*. Typhimurium (H)                                                  Spain               Herrera-Leon et al., [@B87]
  R                    70                                                        SHV-12                                                   ND                                                                                                   *K. pneumoniae* (H)                                                   Portugal            Rodrigues et al., [@B178]
  R+IncFIIk1           300                                                       SHV-2                                                    ND                                                                                                   *K. pneumoniae* (H)                                                   Portugal            Rodrigues et al., [@B178]
  Untypable            90--140 (C)                                               SHV-12 (IS*26*)                                          ND                                                                                                   *K. pneumoniae* (H)                                                   Tunisia             Elhani et al., [@B63]
                       ND                                                        SHV-12 (IS*26*)                                          \-                                                                                                   *E. coli* (H)                                                         UK                  Doumith et al., [@B58]
                       ND                                                        SHV-12 (IS*26*)                                          *bla*~TEM−1~                                                                                         *E. coli* (H)                                                         UK                  Doumith et al., [@B58]
                       ND                                                        SHV-12 (IS*26*)                                          *bla*~TEM-1~, *bla*~*OXA*-1~, *qnrS1*                                                                *E. coli* (H)                                                         UK                  Doumith et al., [@B58]
                       50 (C)                                                    SHV-12                                                   *bla*~NDM-1~                                                                                         *K. pneumoniae* (H)                                                   UAE                 Sonnevend et al., [@B188]

*C, conjugative; NC, non-conjugative; when blank is because not determined*.

*When present, IS26 is indicated in parenthesis*.

*H, human; A, animal (mostly poultry, turkey and broilers; check reference for full description); E, environment. ND, not determined*.

Emergence of Enterobacteriaceae producing β-lactamases in companion animals have been gradually reported, with CTX-M enzymes being prevalent as observed in the human scenario (Rubin and Pitout, [@B179]). Few studies, on both healthy and diagnostic clinical canine and feline samples, report finding other ESBL variants including *bla*~SHV-3~ in the USA (Shaheen et al., [@B184]), *bla*~SHV-2~ in Mexico (Rocha-Gracia et al., [@B177]), *bla*~SHV-12~ in Italy and Poland (Carattoli et al., [@B42]; Rzewuska et al., [@B180]) and *bla*~SHV-12~ in association with *bla*~OXA-48~, *bla*~CMY-2~, *bla*~TEM-1~, *aac(6*′*)-Ib-cr*, and *qnrB2* in Germany (Stolle et al., [@B190]).

Lastly, SHV variants have been detected in imported vegetables in Switzerland together with *bla*~SHV-12~ for the first time in the opportunistic foodborne pathogen *Cronobacter sakazakii* whose potential to cause bacteremia and meningitis is an actual concern (Zurfluh et al., [@B223]). Similar results were observed in vegetables collected in South Korea (Kim et al., [@B106]), salads in the Netherlands (Reuland et al., [@B176]), and Spain (Egea et al., [@B62]), displaying a new route of introduction for ESBLs and pathogenic Enterobacteriaceae.

Plasmid epidemiology of *bla*~SHV−2~, *bla*~SHV−2a~, *bla*~SHV−5~, and *bla*~SHV−12~ {#s6}
====================================================================================

The role of plasmids in the successful spread of β--lactamase genes has been extensively described (Carattoli, [@B39], [@B40]) and, among the SHV family, it finds its best examples in *bla*~SHV-2~, *bla*~SHV-2*a*~, *bla*~SHV-5~, and *bla*~SHV-12~. Combination of these alleles with different dissemination machineries has brought the enzymes to reach diverse niches worldwide (Figure [2](#F2){ref-type="fig"}). Plasmids belonging to seven replicon types (A/C, F, HI2, I1, L/M, N, X3) have been shown to drive the epidemiology of these four predominant SHV ESBLs, although their distribution varies on the plasmid families (Table [4](#T4){ref-type="table"}). Other rep families that have been only incidentally associated with extended-spectrum SHV β--lactamases include the ColE, K, P, and R (Table [4](#T4){ref-type="table"}).

![**Worldwide distribution of plasmid families encoding *bla*~SHV-2~, *bla*~SHV-2a~, *bla*~SHV-5~, and *bla*~SHV-12~**. Inc/rep types are represented in different colors; diverse symbols depict human, bovine, porcine, poultry, wildlife, soil, or wastewater sources. For a complete full reference list see Table [4](#T4){ref-type="table"}.](fmicb-07-01374-g0002){#F2}

IncA/C
------

*bla*~SHV-12~ has been identified on mostly conjugative broad-host range IncA/C plasmids in a variety of bacterial species, including *E. coli, Proteus mirabilis* and *Aeromonas caviae*, isolated from clinical samples in Tunisia, France, Korea and Italy (Marcadé et al., [@B127]; Song et al., [@B187]; Mnif et al., [@B137]; Antonelli et al., [@B11]). *E. coli* isolates recovered from clinical specimens encoding *bla*~SHV-2~, *bla*~SHV-2*a*~, and *bla*~SHV-5~ have been also identified in Tunisia and France (Marcadé et al., [@B127]; Mnif et al., [@B137]), whereas *Providencia stuartii* isolates encoding *bla*~SHV-5~ on either IncA/C or multireplicon IncA/C-R plasmids have been reported from different outbreaks in Greece (Giakkoupi et al., [@B73]; Oikonomou et al., [@B153]). Interestingly, these IncA/C plasmids (130--220 Kb) often carried multiple resistance genes, conferring multidrug resistant phenotypes (Giakkoupi et al., [@B73]; Antonelli et al., [@B11]; Oikonomou et al., [@B153]), resulting in the proliferation of the SHV ESBLs by co-selection.

IncF
----

Plasmids belonging to the narrow-host range IncF group, including plasmids with fused replicons, have been reported to accommodate *bla*~SHV-12~ among clinical *E. coli* isolates from France (IncFII), Tunisia (IncFIA-FIB, IncFII-FIA, IncFII-FIA-FIB) and United Kingdom (IncFIB), but also among food-producing animals from Italy (IncFIB) (Marcadé et al., [@B127]; Bortolaia et al., [@B25]; Doumith et al., [@B58]; Mnif et al., [@B137]). IncF plasmids account for the dissemination of *bla*~SHV-2~ gene among *E. coli* from both clinical specimens in France (IncFIB, IncFII, IncFII-FIB) and food-producing animals (avian and porcine sources) in Canada (IncFIB), as well as in clinical *K. pneumoniae* isolates belonging to ST654 and ST15 from China (IncFIB) and Portugal (IncFII), respectively (Marcadé et al., [@B127]; Wang et al., [@B210]; Pouget et al., [@B168]; Rodrigues et al., [@B178]). Finally, clinical *E. coli* and *K. pneumoniae* from Tunisia were found to encode *bla*~SHV-2*a*~ (Elhani et al., [@B63]; Mnif et al., [@B137]), clinical *E. coli* from Poland encoded *bla*~SHV-5~ on IncF plasmids, as well as clinical *K. pneumoniae* and *Serratia marcescens* from Uruguay (García-Fulgueiras et al., [@B72]; Zienkiewicz et al., [@B219]), whereas the same plasmids have been associated with less prevalent SHV ESBLs (*bla*~SHV-55~ and *bla*~SHV-106~) in clinical *K. pneumoniae* isolates from Portugal (Rodrigues et al., [@B178]).

IncHI2
------

In contrast with the IncA/C and IncF plasmids, the broad-host range IncHI2 group is responsible mainly for the dissemination of *bla*~SHV-12~, although this group has been found incidentally to also accommodate *bla*~SHV-2*a*~ (Mnif et al., [@B137]). Plasmids of this group varying in sizes (95--400 Kb) have been reported to encode *bla*~SHV-12~ in various bacterial species, such as *E. coli, K. pneumoniae, E. cloacae*, and at least three *S. enterica* serotypes (Bredeney, Concord, and Senftenberg) from human specimens with diverse geographical origin (Netherlands, Portugal, Spain, Taiwan, Tunisia; Elhani et al., [@B63]; Veldman et al., [@B203]; Herrera-Leon et al., [@B87]; Mnif et al., [@B137]; Rodrigues et al., [@B178]; Chen C. M. et al., [@B46]). Apart from *bla*~SHV-12~, some of these conjugative plasmids have been reported to co-encode for other resistance genes, including additional SHV ESBLs (*bla*~CTX-*M*-3~, *bla*~CTX-*M*-14~; Veldman et al., [@B203]; Chen C. M. et al., [@B46]).

IncI1
-----

The IncI1 group, consisting of narrow-host range mostly conjugative plasmids, ranks amongst the top facilitators of *bla*~SHV-2~, *bla*~SHV-2*a*~, and *bla*~SHV-12~ genes. The range of bacterial species they have encountered is limited to *E. coli, K. pneumoniae, E. cloacae*, and the *S. enterica* serotypes Concord, Enteritidis, Heidelberg and Kiambu. Nevertheless, IncI1 plasmids (19--340 Kb) occur in very diverse settings: *bla*~SHV-2~- and *bla*~SHV-12~-encoding isolates from human infections (Bulgaria, France, Italy, Spain, Taiwan; Tato et al., [@B196]; Marcadé et al., [@B127]; Accogli et al., [@B2]; de Toro et al., [@B53]; Markovska et al., [@B128]; Chen C. M. et al., [@B46]) and colonization (Ethiopia) (Fabre et al., [@B68]); *bla*~SHV-2~-, *bla*~SHV-2*a*~--, and *bla*~SHV-12~-encoding isolates from poultry (Canada, Italy, Portugal; Bortolaia et al., [@B25], [@B26]; Accogli et al., [@B2]; Pouget et al., [@B168]; Jones-Dias et al., [@B101]), *bla*~SHV-2~- and *bla*~SHV-2*a*~-encoding isolates from pigs (Canada) (Pouget et al., [@B168]); *bla*~SHV-12~-encoding isolates from aquatic birds (Poland) (Literak et al., [@B117]); and *bla*~SHV-12~-encoding isolates from farming soil (Portugal) (Jones-Dias et al., [@B100]). Remarkably, *bla*~SHV-12~ on IncI1 plasmids belonging to pST26 have been identified among *E. coli* isolates of human and animal origin (Accogli et al., [@B2]; Jones-Dias et al., [@B101]), indicating the potential transmission of these *bla*~SHV-12~-encoding vehicles from human to animals and/or vice versa.

IncL/M and IncN
---------------

The broad-host range IncL/M and IncN plasmids contribute to a lesser extent to the epidemiology of *bla*~SHV-2~, *bla*~SHV-2*a*~, *bla*~SHV-5~, and *bla*~SHV-12~ than the above-mentioned families. IncL/M plasmids (60--90 Kb) carrying SHV ESBL genes have been reported only among *E. coli, K. pneumoniae, K. oxytoca*, and *S. enterica* serotype Typhimurium of human origin in Portugal (*bla*~SHV-2~), Tunisia (*bla*~SHV-2*a*~, *bla*~SHV-12~), Italy (*bla*~SHV-5~), USA (*bla*~SHV-5~), and recently in China (*bla*~SHV-12~) (Villa et al., [@B205]; Elhani et al., [@B63]; Mnif et al., [@B137]; Preston et al., [@B169]; Rodrigues et al., [@B178]; Liu et al., [@B119]). The same bacterial species mostly from human sources carry IncN plasmids (\~50 Kb) encoding *bla*~SHV-2~ (China, Senegal), *bla*~SHV-2*a*~ (Tunisia) or *bla*~SHV-12~ (Bulgaria, Netherlands, Norway, Tunisia; Samuelsen et al., [@B181]; Naseer et al., [@B145]; Wang et al., [@B210]; Dierikx et al., [@B54]; Mnif et al., [@B137]; Harrois et al., [@B83]; Markovska et al., [@B128]). Interestingly, the presence of IncN (pST1) plasmids encoding *bla*~SHV-12~ has been reported among *E. coli* from human and animal sources (Dierikx et al., [@B54]), mirroring the situation for IncI1 plasmids and underscoring the contribution of this plasmid family in the transmission of *bla*~SHV-12~ within or between these niches.

IncX3
-----

The IncX3 plasmid subgroup consists of narrow-host range plasmids and plays an important role in the exclusive dissemination of *bla*~SHV-12~. Conjugative plasmids (40--60 Kb) of this subgroup have been identified in diverse bacterial species (*E. coli, K. pneumoniae, C. freundii, E. aerogenes, E. cloacae*), sources (human, animal, environment) and geographical areas (Australia, China, Czech Republic, France, United Arab Emirates, US; Ho et al., [@B90]; Du et al., [@B60]; Kassis-Chikhani et al., [@B105]; Sonnevend et al., [@B188]; Wang et al., [@B209]; Feng et al., [@B69]; Hargreaves et al., [@B82]; Partridge et al., [@B156]; Dobiasova and Dolejska, [@B56]; Huang et al., [@B93]). Interestingly, the majority of these plasmids appear to co-harbor carbapenemase genes (*bla*~KPC-2~, *bla*~NDM-1~), whereas the co-localization of SHV ESBL and carbapenemase genes was reported only on IncA/C or IncA/C-R (*bla*~VIM−1~), IncL/M (*bla*~KPC−2~), and IncN (*bla*~VIM−1~) plasmids (Samuelsen et al., [@B181]; Naseer et al., [@B145]; Giakkoupi et al., [@B73]; Oikonomou et al., [@B153]), enhancing the plasmid potential maintenance among bacterial populations and the subsequent preservation and dissemination of the SHV ESBL genes.

Miscellaneous plasmids
----------------------

*bla*~SHV-12~ has been incidentally found on: (i) a ColE plasmid from *S. enterica* serotype Typhimurium DT104b in Spain (Herrera-Leon et al., [@B87]); (ii) an IncK plasmid from *K. pneumoniae* in the United Kingdom (Timofte et al., [@B199]); (iii) an IncP plasmid from *E. cloacae* in Taiwan (Chen C. M. et al., [@B46]); and (iv) a plasmid assigned to the R replicon type from *K. pneumoniae* in Portugal (Rodrigues et al., [@B178]). *E. coli* and *K. pneumoniae* encoding *bla*~SHV-2~ on IncK plasmids were recovered from animal and human sources in the Netherlands and in Uruguay, respectively (Dierikx et al., [@B55]; García-Fulgueiras et al., [@B72]). IncP plasmids encoding *bla*~SHV-2*a*~ from animals in Canada and *bla*~SHV-5~ from human in Uruguay have also been reported (García-Fulgueiras et al., [@B72]; Pouget et al., [@B168]). Finally, a number of reports highlight the presence of *bla*~SHV-12~ on mostly conjugative non-typeable plasmids, according to the PCR-based replicon-typing scheme (Carattoli et al., [@B41]). These plasmids of human origin, varying between 50 and 140 Kb in size, were mostly detected among *E. coli* from the United Kingdom (Doumith et al., [@B58]) and *K. pneumoniae* from Tunisia (Elhani et al., [@B63]) and United Arab Emirates (Sonnevend et al., [@B188]), underscoring that their dissemination is wider than we know.

IS26 role in *bla*~SHV~ mobilization
------------------------------------

Analysis of the sequences bracketing several SHV ESBL genes (*bla*~SHV-2~, *bla*~SHV-2*a*~, *bla*~SHV-5~, *bla*~SHV-12~, *bla*~SHV-106~, and *bla*~SHV-134~) among Gram-negative bacteria, including Enterobacteriaceae and non-fermenters, revealed that these β-lactamase genes are mostly associated with the IS*26* element (Table [4](#T4){ref-type="table"}, Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). Beside SHV ESBLs, this member of the IS*6* insertion sequence family (Mahillon and Chandler, [@B123]), has been associated with a plethora of resistance genes (Allard et al., [@B7]; Miriagou et al., [@B136]; Post and Hall, [@B167]; Cain et al., [@B36]; Hordijk et al., [@B92]) and has been found to contribute to their expression by supplying a promoter -35 box that can be coupled with a -10 box in the adjacent DNA (Lee et al., [@B113]; Cain and Hall, [@B35]). In contrast to other insertions sequences, it has been suggested that IS*26* transposes preferentially within plasmids rather than into the chromosome (He et al., [@B85]), possibly explaining the linkage of IS*26* and the four predominant SHV ESBL genes with IncA/C (*bla*~SHV-5~, *bla*~SHV-12~), IncF (*bla*~SHV-2*a*~, *bla*~SHV-5~, *bla*~SHV-12~), IncHI2 (*bla*~SHV-12~), IncI1 (*bla*~SHV-12~), IncL/M (*bla*~SHV-2*a*~, *bla*~SHV-5~), IncN (*bla*~SHV-2~), IncP (*bla*~SHV-12~), IncX3 (*bla*~SHV-12~), and non-typeable (*bla*~SHV-12~) plasmids (Table [4](#T4){ref-type="table"}). Similarly to most antibiotic resistance genes, IS*26*-mediated mobilization of SHV ESBL genes on conjugative plasmids facilitated their subsequent intra- and inter-species dissemination (Table [4](#T4){ref-type="table"}). Available sequences of transposons flanked by copies of intact and/or truncated IS*26* elements (Figure [3](#F3){ref-type="fig"}) and coding for SHV ESBL genes show the presence of other co-linear genes originating from the chromosome of *K. pneumoniae* (i.e., *fucA, ygbI, ygbK, ygbJ, ygbM, deoR*; Ho et al., [@B90]; Wang et al., [@B210]; Du et al., [@B60]; Kassis-Chikhani et al., [@B105]; Preston et al., [@B169]; Chen C. M. et al., [@B46]; Feng et al., [@B69]; Giakkoupi et al., [@B73]), likely underscoring the involvement of IS*26* in the mobilization of *bla*~SHV~ from the chromosome of *K. pneumoniae*, as previously suggested (Haeggman et al., [@B77]).

![**Schematic representation of *bla*~SHV~ genetic surroundings and IS*26* association**. Common occurring features are color coded. Map is not to scale. References: IncN (Wang et al., [@B210]); IncA/C (Giakkoupi et al., [@B73]); IncL/M (Preston et al., [@B169]); IncHI2, IncI1, IncP (Chen C. M. et al., [@B46]); IncX3 (Ho et al., [@B90]; Du et al., [@B60]; Kassis-Chikhani et al., [@B105]; Feng et al., [@B69]).](fmicb-07-01374-g0003){#F3}

Outside of the enterobacteriaceae and a few peculiar SHV ESBLs {#s7}
==============================================================

SHV β--lactamases have virtually invaded all human, environmental and animal sceneries, mostly associated to Enterobacteriaceae. In recent years, the first reports of alternative bacterial hosts have been described, notably in Aeromonads, ubiquitous in aquatic habitats and occasionally able to cause human infections. *bla*~SHV-12~ was detected, in association with *bla*~FOX-2~ and *bla*~CTX-*M*-15~, on the chromosome of the foodborne pathogens *A. caviae* and *Aeromonas hydrophila* from wild-growing mussels from Croatia (Maravić et al., [@B126]). The first identification of plasmid-encoded SHV-12, together with VIM-1, occurred in clinical *A. caviae* accountable for a newborn bloodstream infection (Antonelli et al., [@B11]). The coproduction of these enzymes highlights the potential risks for public health and the role of Aeromonads as reservoirs and dissemination tools of resistance determinants in both environmental and clinical settings.

Occasionally, SHV ESBL-producing *Pseudomonas aeruginosa* can be detected in nosocomial settings and can pose a serious threat as healthcare-associated infection in many regions of the world. *bla*~SHV-2*a*~ was first identified on the chromosome of a 1995 clinical *P. aeruginosa* strain, with high sequence homology to plasmid pMPA2a from *K. pneumoniae* indicating a likely enterobacterial gene origin (Naas et al., [@B143]). Subsequent studies demonstrated the insertion of *bla*~SHV~ alleles into *P. aeruginosa* chromosome: *bla*~SHV~ in China (Chen Z. et al., [@B47]) and Iran (Shahcheraghi et al., [@B183]); *bla*~SHV-5~ (Poirel et al., [@B166]) and *bla*~SHV-12~ (Neonakis et al., [@B146]) in Greece; and *bla*~SHV-2*a*~ in Tunisia (Mansour et al., [@B124]) and France (Hocquet et al., [@B91]; Jeannot et al., [@B95]). The role of IS26 in the mobilization of *bla*~SHV-12~ was demonstrated by the chromosomal insertion of an IS26 composite transposon (\>24 kb) thanks to the co-mobilization of antibiotic resistance *aac(6*′*)-Ib*, which confers amikacin resistance, likely occurred during the clinical course of a burn infection, immediately after amikacin administration (Uemura et al., [@B202]). *bla*~SHV-5~, *bla*~SHV-11~, *bla*~SHV-12~ were also detected in different combinations, together with *bla*~TEM-1*b*~, on various plasmids in Thailand (Chanawong et al., [@B45]).

Finally, one of the most effective associations outside of the Enterobacteriaceae is with *Acinetobacter baumannii*, contributing to the worrisome spread of ESBL-producing strains especially in clinical outbreaks (Blackwell et al., [@B22]). Plasmid transfer from nosocomial SHV-encoding Enterobacteriaceae seems to be responsible for this phenomenon, as observed for SHV-12 in the Netherlands (Naiemi et al., [@B144]), or SHV-5 in the USA, a country where this variant is the most prevalent ESBL gene in Enterobacteriaceae (Naas et al., [@B142]).

Among all ESBL SHV β-lactamases, few enzymes deserve special consideration because of their unique enzymatic features.

SHV-38 is a unique allelic variant of the SHV family to have an expanded-spectrum to carbapenems. It was first described in *K. pneumoniae* from France (Poirel et al., [@B165]) and it holds a point mutation (Ala^146^Val) compared to the chromosome-encoded SHV-1. Among all 46 available SHV ESBL variants, only SHV-38 possess the Ala^146^Val substitution (Table [2](#T2){ref-type="table"}), likely inducing subtle structural conformational changes favoring imipenem but not meropenem hydrolysis (Walther-Rasmussen and Høiby, [@B208]).

SHV-129 is a novel clinically acquired variant identified in 2012 from an Italian *E. coli* isolate (Table [1](#T1){ref-type="table"}; Lascols et al., [@B112]) and it represents an interesting example of enzyme evolution due to antibiotic pressure. Alongside two well-known amino acid substitutions (Gly^238^Ser, Glu^240^Lys), SHV-129 contains new substitutions, Arg^275^Leu and Asn^146^Asp). The latter was recently demonstrated to be the first global suppressor substitution identified in the SHV β-lactamase family (Winkler and Bonomo, [@B213]), likely helping in protein stabilization and functionality, as well as in the ability of the enzyme to acquire additional substitutions. It is also proposed that due to the increasing clinical use of cefepime, SHV-129 might have evolved from SHV-2 or SHV-5 in an alternative conformation to expand its spectrum to hydrolyze cefepime, as mirrored by the kinetic parameters of the three enzymes (Table [3](#T3){ref-type="table"}).

Finally, SHV-2 can be located on both chromosome and self-transmissible plasmids (Table [4](#T4){ref-type="table"}; Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). Association of *bla*~SHV-2~ with RCS47, a P1-like bacteriophage that infects and lysogenizes *E. coli* and several other enteric bacteria, was recently reported (Billard-Pomares et al., [@B21]). *bla*~SHV-2~ is flanked by two IS*26* elements that likely drove the insertion in the phage backbone. The P1-like prophages were found with high prevalence in natural *E. coli* of both animal and human origin, including ESBL-producing isolates. This kind of association was already reported for other β-lactamases (*bla*~TEM~, *bla*~CTX-*M*~, and *mecA*) from river and urban sewage water (von Wintersdorff et al., [@B207]), suggesting that bacteriophages might play a wider role in favoring horizontal transfer of antibiotic resistance determinants than initially thought (Muniesa et al., [@B139]).

Concluding remarks {#s8}
==================

Tzouvelekis and Bonomo suggested than "it will not be surprising if (SHV) enzymes will continue to expand their substrate spectrum as long as the current antibiotics, or novel ones derived from the basic β-lactam structure, are used" (Tzouvelekis and Bonomo, [@B201]). In the last two decades we observed the appearance of multiple SHV-type variants, with few ones significantly expanding their substrate. One exception is represented by SHV-38, the only known SHV allelic variant able to hydrolyze carbapenems (Poirel et al., [@B165]), a feature that has not been associated with any TEM or CTX-M enzyme. In this image resides the fate of SHV extended β-lactamases, unable to undergo the dominant propagation observed, for instance, for the CTX-M family but yet contributing to β-lactam resistance in a not negligible way.

The persistence of SHV enzymes in the bacterial community might also be secured by co-selection with emerging resistance genes. Association of *bla*~SHV-12~ with IncX3 plasmids carrying carbapenemase genes *bla*~KPC−2~ and *bla*~NDM~ has been observed in recent years (Table [4](#T4){ref-type="table"}) and it seems to be a phenomenon occurring in clinical carbapenem-resistant Enterobacteriaceae worldwide (Kassis-Chikhani et al., [@B105]; Sonnevend et al., [@B188]; Partridge et al., [@B156]; Huang et al., [@B93]). As highlighted in this review, the association of successful variants *bla*~SHV-2~, *bla*~SHV-2*a*~, *bla*~SHV-5~, and *bla*~SHV-12~ with different families of conjugative plasmids (IncA/C, IncF, IncHI2) might also underlie the colonization of virtually all ecological niches encompassing food producing animals, aquatic environment, wildlife, companion animals, and vegetables. Plasmid mediated transfer from nosocomial Enterobacteriaceae enabled SHV dispersion toward alternative bacterial hosts such as the emerging nosocomial pathogens of aquatic origin *S. maltophilia* and *A. caviae*, or contributed to the worrisome spread of ESBL-producing strains of *A. baumannii* and *P. aeruginosa*. Most interestingly, the ubiquitous presence of SHV ESBL genes and plasmids is suggestive for transmission in human, animals, and the environment, most likely through the food chain, highlighting the potential risks for public health and endorsing a one health research approach.

Overall, SHV ESBL enzymes have kept a stable role in antibiotic resistance over the years. Allele diversification is still occurring, the latest variant being identified in *E. cloacae* in 2014 (*bla*~SHV-183~), and effective associations with new genetic platforms are taking place helping expansion toward novel bacterial hosts and reservoirs.
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^1^Of the 194 variants available on line (<http://www.lahey.org/studies>), 5 were withdrawn or invalidated as only partial sequence.
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